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Abstract 
Staphylococcus pseudintermedius is part of the normal microbiota of dogs and 
cats. Since the mid-1980s, an ever-increasing number of methicillin-resistant S. 
pseudintermedius (MRSP) isolates have been reported. The situation worsened 
in the mid-2000s, when two predominant MRSP clones, ST71 (sequence type 71) 
and ST68, spread through Europe and North America, respectively. MRSP 
isolates are commonly multidrug resistant (MDR), and are thus capable of 
causing infections that do not respond to routinely used antimicrobials. MRSP 
appeared in the small animal population of Finland in the late 2000s, also causing 
numerous infections at the Veterinary Teaching Hospital (VTH) of the University 
of Helsinki. Finnish surveillance data also indicated that the proportion of MRSP 
among S. pseudintermedius isolates drastically increased in 2009–2011. MRSP 
has been under intense study worldwide in recent years, but no data on the 
epidemiology of the bacterium in Finland have been published. 
This thesis study aimed to explore the epidemiology of MRSP in the Finnish 
small animal population, and to report antimicrobial susceptibility for S. 
pseudintermedius. This was done by investigating and describing the MRSP 
outbreak at the VTH, and investigating risk factors for patients being colonized or 
infected by MRSP in the hospital during the outbreak. The prevalence of MRSP 
and the risk factors for MRSP carriage were investigated in a canine 
subpopulation at the Guide Dog School for the Visually Impaired. The 
susceptibility of S. pseudintermedius isolates to antimicrobials in 2011–2015 was 
investigated using data from the Clinical Microbiology Laboratory (CML) of the 
Faculty of Veterinary Medicine, University of Helsinki. Risk factors for an S. 
pseudintermedius isolate being MRSP, as well as for a screening specimen 
revealing MRPS, were also investigated. Furthermore, the molecular 
epidemiology of all MRSP isolates stored in 2010–2014 was investigated using 
pulsed-field gel electrophoresis (PFGE), multi-locus sequence typing (MLST) and 
staphylococcal cassette chromosome mec (SCCmec) typing. 
Antimicrobial therapy, whether previous or ongoing during sampling, was 
identified as a risk factor for MRSP in all studies. Furthermore, a prolonged 
hospital stay and veterinary visits were identifiable risk factors among guide dogs. 
An S. pseudintermedius isolate originating from a private clinic (versus the VTH) 
was a significant risk factor for MRSP among clinical specimens. The same could 
be seen among screening specimens from patients with risk factors for MRSP. In 
addition, it was noted that a sizeable proportion (~20–60%) of animals in the 
studies had been or were being treated with antimicrobials. 
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During the outbreak at the VTH, rigorous hygiene and barrier measures were 
necessary to achieve control. ST71, the MRSP clone that caused the outbreak, was 
the predominant clone in 2010–2011, accounting for over 50% of MRSP isolates, 
even among non-outbreak-related isolates. By 2014, however, the situation had 
changed, as ST71 represented only ~10% of MRSP isolates. MRSP clones 
belonging to CC45 (clonal complex 45) and CC258, as well as a plethora of 
unrelated STs, dominated the MRSP population by that time. SCCmec type IV 
was detected in a majority of different STs, indicating the horizontal spread of 
resistance genes. 
The prevalence of MRSP was only 3% among guide dogs. The proportion of 
clinical specimens from small animals that revealed MRSP was similar, being 
2.5%. However, 9% of screening specimens from high-risk patients revealed 
MRSP. Overall, 14% of S. pseudintermedius isolates were MRSP. Roughly 30–
40% of isolates were not susceptible to alternative antimicrobials, such as 
lincosamides, macrolides, or tetracyclines. MRSP in feline specimens was rare 
(<1% in both clinical and screening specimens after 2011). 
Our results give further credence to the hypothesis that antimicrobial therapy 
and contact with the veterinary environment are risk factors for MRSP in small 
animals. However, cats do not appear to be a significant source of MRSP. Our data 
suggest that the epidemiology of MRSP has changed from a predominantly clonal 
spread to a mix of clonal spread and the spread of genetic elements. The resistance 
rates among S. pseudintermedius are at an alarming level. Decisive action, 
including the use of non-antimicrobial treatments whenever feasible and more 
prudent use of antimicrobials, is required to improve the situation.  
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1 Introduction 
Staphylococcus intermedius was originally discovered in 1976 (Hajek, 1976) and 
later renamed in 2005 (Devriese et al., 2005) as Staphylococcus 
pseudintermedius. It is a significant opportunistic pathogen of small animals. It 
is frequently associated with dermatitis and otitis, as well as surgical site and 
urinary tract infections (Weese and van Duijkeren, 2010; Windahl et al., 2015). 
Since the beginning of the 21st century, an increasing number of methicillin-
resistant isolates (methicillin resistant Staphylococcus pseudintermedius, 
MRSP) have been discovered. The majority of MRSP isolates are multidrug 
resistant (MDR), and infections caused by these may be very difficult to treat due 
to the lack of effective antimicrobial agents (van Duijkeren et al., 2011a). These 
bacteria also have the potential to spread in veterinary clinics and hospitals 
(Bergstrom et al., 2012; Zubeir et al., 2007). Due to the aforementioned factors, 
MRSP has an impact on the veterinary medical community, and the general 
public, by increasing treatment costs and compromising animal health and 
welfare. The spread of resistant bacteria may also impact on public health, as S. 
pseudintermedius can be spread between humans and animals (van Duijkeren et 
al., 2008; van Duijkeren et al., 2011b), and may cause infections in humans 
(Borjesson et al., 2014; Starlander et al., 2014). Additionally, the spread of 
resistance genes between different species of staphylococci, e.g. from S. 
pseudintermedius to Staphylococcus aureus, via mobile genetic elements has the 
potential to cause the proliferation of MRSA (Hanssen and Ericson Sollid, 2006). 
This doctoral thesis explores the infection and molecular epidemiology of 
MRSP by investigating the antimicrobial resistance of Finnish S. 
pseudintermedius isolates, determining the prevalence of MRSP in Finnish guide 
dogs and patients with risk factors for MRSP, assessing the crude prevalence of 
MRSP based on results from clinical specimens, investigating factors that 
predispose to MRSP infection or colonization, and exploring the genetic 
relatedness of MRSP isolates in Finland. 
To investigate susceptibility and molecular epidemiology, a collection of S. 
pseudintermedius and MRSP strains isolated in the Clinical Microbiology 
Laboratory (CML) of the Faculty of Veterinary Medicine at the University of 
Helsinki was examined. Risk factors were investigated using cross-sectional 
studies on an MRSP outbreak at the University of Helsinki Veterinary Teaching 
Hospital (VTH), data from the Guide Dog School of the Finnish Federation of the 
Visually Impaired, and laboratory data. The molecular epidemiology of MRSP 
was studied by pulsed-field gel electrophoresis (PFGE), multi-locus sequence 
typing (MLST) and staphylococcal cassette chromosome mec (SCCmec) analyses.
Review of the literature 
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2 Review of the literature 
2.1 Staphylococcus pseudintermedius 
Staphylococci are Gram-positive, catalase-positive cocci, and members of the 
Staphylococcacae family (Becker and von Eiff, 2011). These bacteria are common 
commensals of the skin and mucous membranes in mammals (including humans) 
and birds (Becker and von Eiff, 2011). S. pseudintermedius (previously identified 
and named as S. intermedius) is part of the normal microbiota of dogs and cats 
(Cox et al., 1985; Devriese and De Pelsmaecker, 1987; Devriese et al., 2005; van 
Duijkeren et al., 2011a), but is also an opportunistic pathogen. In general, cats 
carry S. pseudintermedius at a lower rate than do dogs (Cox et al., 1988; Cox et 
al., 1985; Lilenbaum et al., 1999; Lilenbaum et al., 1998). The bacterium is 
commonly associated with ear and skin infections in the dog and cat (Fitzgerald, 
2009; Huerta et al., 2011; Kadlec et al., 2011; Kania et al., 2004). Staphylococcal 
infections are traditionally treated with first-generation cephalosporins or 
amoxicillin potentiated with clavulanic acid. Other treatment options include a 
combination of sulfonamides and trimethoprim, lincosamides such as 
clindamycin, or macrolides such as erythromycin and tylosin (Sykes, 2013). The 
susceptibility of staphylococci to these drugs has declined in previous years. One 
example of this is the rapidly increasing resistance to methicillin, which has led 
to fewer therapeutic alternatives (Perreten et al., 2010). 
2.2 Taxonomy and identification of S. pseudintermedius 
S. pseudintermedius, first described in 2005 by Devriese et al. (2005) and 
isolated from a cat, a dog, a horse, and a parrot (Devriese et al., 2005), is part of 
the Staphylococcus intermedius group (SIG). Two additional species, 
Staphylococcus intermedius and Staphylococcus delphini, also belong to this 
group. S. intermedius was initially identified in 1976 from pigeons, dogs, mink, 
and horses (Hajek, 1976). S. delphini was originally found in dolphins (Varaldo et 
al., 1988). The taxonomy of the SIG is presented in Figure 1.  
Previously identified canine S. intermedius isolates have been reclassified as 
S. pseudintermedius, as identification based on sodA and cpn60 sequencing 
allows the differentiation of SIG species (Bannoehr et al., 2007; Sasaki et al., 
2007b). The current consensus is that canine isolates belonging to the SIG can be 
presumptively reported as S. pseudintermedius (Devriese et al., 2009). As such, 
it should be noted that canine S. intermedius isolates, particularly prior to 2005, 
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are probably S. pseudintermedius isolates. As a consequence of this, the 
abbreviation MRSI (methicillin-resistant Staphylococcus intermedius) has been 
replaced by the abbreviation MRSP. Furthermore, all S. intermedius findings 
from small animals will be presumed to be S. pseudintermedius for the purpose 
of this review, as was suggested by Devriese et al. (2009), and reported as S. 
(pseud)intermedius. 
 
 
Figure 1 The taxonomy of the Staphylococcus intermedius group (gray area) and related 
bacteria. The scale indicates the % difference in average nucleotide identity. 
Simplified from Ben Zakour et al. (2012). 
 
The biochemical differentiation of species belonging to SIG can be difficult. While 
S. intermedius and S. pseudintermedius can be differentiated, for example,  by 
arginine dihydrolase and D-mannitol-tests, S. delphini and S. pseudintermedius 
cannot be reliably differentiated using biochemical reactions (Sasaki et al., 
2007b). Biochemical test kits, such as the ID32 Staph (bioMérieux, France), are 
also unable to differentiate the species within this group (Layer et al., 2006; 
Sasaki et al., 2007b). 
However, a simple PCR-RFLP (polymerase chain reaction - restriction 
fragment length polymorphism) method in which the pta (phosphate 
acetyltransferase) gene is first amplified and then restricted using an MboI 
restriction enzyme has been shown to be useful in differentiating S. 
pseudintermedius from other members of the SIG (Bannoehr et al., 2009). 
Although SIG members are very similar, differention between them may also be 
achieved by 16S rRNA sequencing, the most common method for identifying 
bacterial species (Devriese et al., 2005). Furthermore, mass spectroscopy, such 
as MALDI-TOF (Matrix Assisted Light Desorption Ionization - Time of Flight) has 
been studied as a tool for distinguishing the members of the SIG, with promising 
results (Decristophoris et al., 2011). 
Staphylococcus intermedius 
Staphylococcus pseudintermedius 
Staphylococcus delphini 
Staphylococcus carnosus 
Staphylococcus saprophyticus 
Staphylococcus heamolyticus 
Staphylococcus epidermidis 
Staphylococcus aureus 
Micrococcus caseolyticus 
5 % 
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In human medicine, the importance of S. pseudintermedius and other 
members of the SIG as pathogens may previously have been underestimated, as 
misidentification as Staphylococcus aureus is known to occur (Borjesson et al., 
2014). There is even a study reporting MSSP being misidentified as MRSA using 
common clinical laboratory techniques (Pottumarthy et al., 2004). Lee et al. 
(2015) recently described an algorithm for identifying SIG members in a clinical 
laboratory setting by utilizing colony morphology, a latex agglutination test, 
DNase test, and VITEK 2. 
2.3 Virulence factors 
The infections caused by S. pseudintermedius and S. aureus are fairly similar, 
although the latter has been studied in greater detail (Weese and van Duijkeren, 
2010). S. pseudintermedius is associated with a plethora of infections in 
companion animals, such as pyoderma, otitis, surgical wound infections, cystitis, 
metritis, and osteomyelitis (Cabassu and Moissonnier, 2007; Fitzgerald, 2009; 
Huerta et al., 2011; Kania et al., 2004; Ruscher et al., 2009; Weese and van 
Duijkeren, 2010). 
Some factors affecting the virulence of S. pseudintermedius have been 
identified. Features in common with S. aureus, such as coagulase, and many 
proteases and thermonucleases, have been discovered in S. pseudintermedius 
(Fitzgerald, 2009). S. pseudintermedius also produces toxins such as hemolysin 
(alpha and beta-hemolysin), exfoliative toxin and enterotoxins (Quinn et al., 
2011). Exfoliative toxin likely plays an important role in the development of 
staphylococcal pyoderma, as it can cause subcorneal clefts in the canine epidermis 
(Iyori et al., 2011). Iyori et al. (2011) demonstrated that the exfoliative toxin 
producing orf gene was more common in S. pseudintermedius isolates from dogs 
with pyoderma compared to healthy dogs (23% vs. 6%). Also, Terauchi et al. 
(2003) isolated an exfoliative toxin-like toxin that showed strong cell rounding 
activity from S. (pseud)intermedius isolates derived from dogs with pyoderma. 
The classical virulence factor of S. aureus, Panton-Valentine Leucocidin (PVL), 
has not been detected in S. pseudintermedius (Bardiau et al., 2013; Wedley et al., 
2014; Weese et al., 2009). Leukotoxin production has nevertheless been 
discovered among canine S. pseudintermedius isolates (Futagawa-Saito et al., 
2004). 
Furthermore, S. pseudintermedius has the ability to bind to fibrinogen, 
fibronectin, and cytokeratin (Geoghegan et al., 2009), common microbial surface 
components recognizing adhesive matrix molecules found in S. aureus 
(Heilmann, 2011). S. pseudintermedius also carries an immunoglobulin-binding 
protein that resembles staphylococcal protein A (spa) found in S. aureus 
(Moodley et al., 2009). In addition, the bacterium has the ability to form biofilm 
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(Osland et al., 2012), a characteristic that results in increased tolerance to 
antimicrobials and is a well-established problem with infections involving 
orthopedic implants (Olsen, 2015). Furthermore, at least one study indicates that 
agr (accessory gene regulator) gene homologues, which are involved in quorum 
sensing, have been detected in some S. (pseud)intermedius isolates (Dufour et al., 
2002). 
 
2.4 Infection, colonization and contamination 
As with any bacterium, an animal may be classified as having an infection, 
colonization or contamination by the bacterium. An infection implies that the 
bacterium has been able to avert the hosts’ primary immune response and has 
established an infection accompanied by an inflammatory response (redness, 
swelling, pain, warmth, and loss of function). This may be localized, e.g. an outer 
ear infection, or generalized, i.e. systemic. 
Colonization is a state where the animal is a carrier of the bacterium for a 
prolonged time, i.e. the bacterium may be repeatedly isolated from subsequent 
specimens from the same animal. Colonization with S. pseudintermedius is very 
common in dogs, as it is considered part of the normal microbiota (Cox et al., 
1985; Devriese and De Pelsmaecker, 1987; van Duijkeren et al., 2011a). 
Colonization with methicillin-resistant Staphylococcus pseudintermedius 
(MRSP) is less common (Beck et al., 2012), and there are indications that some 
dogs may eliminate MRSP over time (Windahl et al., 2012). Colonized animals 
are probably an important method of spread for MRSP (as they are for MRSA), as 
they do not show symptoms of disease (van Duijkeren et al., 2011a; Weese, 2010). 
The third category, contamination, is a state whereby the animal is only a 
transient carrier of the bacterium. In these cases, the bacterium can usually be 
isolated only once from the animal, while subsequent specimens do not reveal it. 
It may be difficult to distinguish between colonization and contamination, as it is 
dependent upon factors such as the interval with which specimens are obtained. 
2.5 Methicillin resistance in S. pseudintermedius 
MRSP, as well as most other methicillin-resistant staphylococci, carry the mecA 
gene in their DNA (Ubukata et al., 1989). mecA resides in a mobile genetic 
element, a staphylococcal cassette chromosome (SCC), designated SCCmec, of 
which there are currently eleven (I–XI) different types (IWG-SCC, 2017b). The 
features of SCCmec are further discussed in section 2.8.2. It is believed that mecA 
originated in Staphylococcus scuiri, one of the most primitive species of 
Review of the literature 
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staphylococci (Couto et al., 1996). Some S. aureus and coagulase-negative 
Staphylococcus sp. (CoNS) isolates carry a mecA homolog, mecC, which has thus 
far been reported to only be carried by SCCmec XI (Liu et al., 2016; Shore et al., 
2011). Neither mecC nor SCCmec XI have yet been detected in S. 
pseudintermedius. The mecA gene codes for a specific penicillin binding protein 
(PBP2a) that methicillin and other beta-lactam-class drugs bind to ineffectively 
(Ubukata et al., 1989). In the bacterial cell, PBPs are responsible for the cross-
linking of the glycopeptide polymer units in the peptidoglycan layer of the cell 
wall. Beta-lactams inhibit this cross-linking, causing defects in cell wall synthesis, 
which leads to the death of actively dividing cells (Prescott, 2013a). Due to the 
ineffective binding of beta-lactams to the altered PBPs, MRSP is resistant to this 
entire class of antimicrobials, except for ceftaroline, a 5th generation 
cephalosporin (Duplessis and Crum-Cianflone, 2011).  
Using conventional methods, the identification of MRSP from a clinical 
specimen takes at least 2–3 days. Presumptive identification of MRSP is based on 
species identification and resistance to oxacillin, a methicillin analogue 
commonly used for the screening of methicillin-resistant staphylococci (MRS) 
(CLSI, 2013a, b). The use of a 10-μg oxacillin disk has been shown to predict 
methicillin resistance (i.e. the presence of mecA) in S. pseudintermedius very well 
when the zone of inhibition (ZOI) is ≤17 mm (Bemis et al., 2009).  Cefoxitin, 
which is the main method to screen for methicillin resistance in S. aureus, is not 
a sensitive method to screen for mecA in S. pseudintermedius (Bemis et al., 2009; 
Bemis et al., 2012). Further testing is required to confirm the isolate as MRSP. 
This is most reliably done by PCR to detect the mecA gene (van Duijkeren et al., 
2011a). This method may, however, not be available in some veterinary 
laboratories. An alternative method is the detection of the altered surface protein 
by a latex-based agglutination method. The sensitivity and specificity of latex 
agglutination tests have been shown to be high for S. aureus (Baddour et al., 
2007; Nakatomi and Sugiyama, 1998). However, caution should be used when 
investigating atypical isolates that do not grow on routinely used testing media, 
as cefoxitin inducement of PBP2a production may be required (Miller et al., 
2017). While agglutination tests are a useful tool to detect PBP2a in S. aureus, 
and have been used in studies regarding S. pseudintermedius, they have not been 
validated for MRSP. Indeed, at least one study has reported cases where MSSP 
isolates have given false-positive PBP2a latex agglutination results (Pottumarthy 
et al., 2004). It would be important to develop a cost-effective method for rapid 
and accurate MRSP detection, such as the tests developed for MRSA (Patel et al., 
2015). 
Infections caused by MRSP can be difficult to treat owing to the fact that it is 
also frequently resistant to a number of other antimicrobial classes (Borjesson et 
al., 2012; Perreten et al., 2010) (see section 2.6). In addition, MRSP can cause 
problems in veterinary hospitals and clinics, as it is capable of nosocomial spread 
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(Caveney et al., 2012; van Duijkeren et al., 2011a) (see section 2.9.2). The 
proportion of MRSP among S. pseudintermedius isolates and the prevalence of 
MRSP among animals varies between studies and countries, but both figures have 
increased in recent years. The occurrence of MRSP is further discussed in section 
2.9. 
 
2.6 Resistance to other antimicrobials 
2.6.1 Resistance to macrolides and lincosamides 
Macrolides and lincosamides both inhibit protein synthesis in bacteria by binding 
to the 50S subunit of the ribosome (Giguère, 2013a, b). Macrolides inhibit the 
transpeptidation and translocation process, thus causing premature detachment 
of the polypeptide chain (Giguère, 2013b), while lincosamides inhibit peptidyl 
transferases (Giguère, 2013a). These mechanisms are very similar, and the 
ribosomal binding sites of these classes of drugs are the same or closely related 
(Giguère, 2013a). Macrolide drugs commonly used in dogs and cats include 
erythromycin, clarithromycin, azithromycin, and tylosin, while the most 
commonly used lincosamide is clindamycin (Sykes, 2013). 
Resistance to macrolides and lincosamides is caused by the methylation of 
rRNA (most commonly), efflux mechanisms, or enzymatic inactivation (Giguère, 
2013a, b). Cross-resistance between macrolides and lincosamides, as well as 
streptogramin B (also called MLSB), is common (Giguère, 2013a). This resistance 
is due to the methylation of the 23S ribosomal RNA (rRNA), which prevents the 
drug from binding to this site (Lai and Weisblum, 1971; Leclercq and Courvalin, 
1991). Methylases are encoded by the erm gene family (Weisblum, 1995), of which 
the most common representative among MRSP isolates is ermB (Perreten et al., 
2010). Cross-resistance among MLSB can be either constitutive, conferring 
resistance to the entire group, or dissociated inducible, where the bacteria appear 
susceptible to lincosamides, but rapidly develop resistance during treatment 
(Giguère, 2013a). This inducible resistance should be tested for during routine 
susceptibility testing (CLSI, 2013a; Gold and Lawhon, 2013). 
Resistance to macrolides is prevalent among S. pseudintermedius, with 
resistant strains making up 9% to 28% of investigated isolates (Ganiere et al., 
2005; Intorre et al., 2007; Norstrom et al., 2009; Rubin et al., 2011; Vanni et al., 
2009; Windahl et al., 2015). Macrolide resistance among MRSP isolates is very 
common (87–100%) (Kjellman et al., 2015; Perreten et al., 2010; Ruscher et al., 
2010; Sasaki et al., 2007a). 
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Due to the aforementioned cross-resistance, resistance to lincosamides among 
S. pseudintermedius is roughly as common as macrolide resistance, ranging from 
10 to 22% (Ganiere et al., 2005; Kawakami et al., 2010; Vanni et al., 2009), 
although one study found resistance to clindamycin as high as 99% (Casagrande 
Proietti et al., 2012). Macrolides were not tested in that study. Resistance among 
MRSP isolates is in general significantly higher, being 87–100% (De Lucia et al., 
2011; Kawakami et al., 2010; Kjellman et al., 2015; Perreten et al., 2010; Ruscher 
et al., 2010; Sasaki et al., 2007a). The prevalence of inducible clindamycin 
resistance among S. pseudintermedius isolates has been reported to be 5% 
(Chanchaithong and Prapasarakul, 2015). Inducible clindamycin resistance 
among MRSP isolates is rare, as it is far more common for MRSP to be resistant 
to both macrolides and lincosamides, i.e. constitutively resistant (Faires et al., 
2009). 
2.6.2 Resistance to tetracyclines 
Tetracyclines inhibit protein synthesis in the bacterial cell by binding to the 30S 
subunit of the ribosome (del Castillo, 2013). Resistance is most commonly 
mediated by either an efflux system or ribosomal protection proteins that detach 
tetracyclines from their binding sites (del Castillo, 2013; Roberts, 1996). The 
spectrum of resistance among tetracyclines is associated with the type of tet gene, 
the main mediator of tetracycline resistance. tet(K) confers resistance to 
tetracycline, but not to doxycycline and minocycline (Frank and Loeffler, 2012). 
tet(K) genes are common in the main European MRSP clone, ST71 (Perreten et 
al., 2010). tet(M) genes, on the other hand, confer resistance to all mentioned 
tetracyclines (Frank and Loeffler, 2012). Differences in tetracycline and 
doxycycline resistance are probably due to the presence of either tet(M) or tet(K) 
(Ganiere et al., 2005). More recent studies suggest that tet(M) has become an 
important mediator of resistance to tetracyclines among S. pseudintermedius, 
(Maaland et al., 2013; Norstrom et al., 2009). 
Tetracycline resistance is quite common among S. pseudintermedius isolates, 
with percentages ranging from 24 to 46%, (Ganiere et al., 2005; Rubin et al., 
2011; Windahl et al., 2015). However, a study by Casagrande Proietti et al. (2012) 
revealed very high levels of resistance to doxycycline (96%), although the 
selection criteria for the investigated isolates were not disclosed. Resistance 
among MRSP isolates is generally higher (46–90%) (Casagrande Proietti et al., 
2012; Kjellman et al., 2015; Perreten et al., 2010). 
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2.6.3 Resistance to fluoroquinolones 
Fluoroquinolones are bactericidal antimicrobials mainly used to treat infections 
caused by Gram-negative bacteria (Sykes, 2013). Their effect is based on their 
ability to cause defects in the negative supercoiling of DNA in the bacterial cell by 
targeting DNA topoisomerases (Giguère and Dowling, 2013). It has been found 
that different fluoroquinolones primarily target either topoisomerase IV or DNA 
gyrase (topoisomerase II), or both. Type I fluoroquinolones (e.g. ciprofloxacin, 
and levofloxacin) mainly target topoisomerase IV, type II fluoroquinolones (e.g. 
nadifloxacin) mainly target DNA gyrase, and type III fluoroquinolones (e.g. 
moxifloxacin and pradofloxacin) target both equally (dual-target property) (Takei 
et al., 2001; Wetzstein, 2005). 
Fluoroquinolones commonly used in veterinary medicine primarily represent 
two different generations of the drug class, II and III (Giguère and Dowling, 
2013). Enrofloxacin, representing generation II, is the most common 
fluoroquinolone in veterinary medicine, while pradofloxacin is the sole 
generation III fluoroquinolone approved for animal use (Giguère and Dowling, 
2013). Pradofloxacin is more potent against S. pseudintermedius than 
enrofloxacin (Blondeau et al., 2012; Schink et al., 2013; Silley et al., 2012). This 
is probably because third-generation fluoroquinolones have a preferential affinity 
for topoisomerase IV as a primary target (Drlica and Malik, 2003), although 
pradofloxacin does display dual targeting of both topoisomerase IV and DNA 
gyrase (Wetzstein, 2005). Resistance to fluoroquinolones can be caused by target 
modification, decreased permeability, efflux, and target protection. These 
mechanisms are not mutually exclusive and may appear simultaneously (Giguère 
and Dowling, 2013). Mutations in the gyrA gene confer fluoroquinolone 
resistance in S. pseudintermedius (Intorre et al., 2007). 
Reports regarding the susceptibility of S. pseudintermedius to enrofloxacin 
have reported resistance figures between 0% and 23% (Ganiere et al., 2005; 
Intorre et al., 2007; Lilenbaum et al., 1999; Rubin et al., 2011; Vanni et al., 2009; 
Windahl et al., 2015), while respective figures for MRSP are markedly higher, 
being 45–100% (De Lucia et al., 2011; Morris et al., 2006; Perreten et al., 2010). 
Kjellman et al. (2015) found that fluoroquinolone resistance was associated with 
MRSP ST71, as all representatives of that lineage displayed resistance to 
ciprofloxacin (enrofloxacin was not tested). 
Pradofloxacin has thus far not been readily available for susceptibility testing, 
and epidemiological data regarding the prevalence of pradofloxacin resistance in 
S. pseudintermedius are therefore scarce (Ganiere et al., 2005; Kizerwetter-
Swida et al., 2016). Extensive data on cross-resistance between enrofloxacin and 
pradofloxacin have not yet been published, although Ganiere et al. (2005) did 
find one S. pseudintermedius isolate that was resistant to enrofloxacin and 
marbofloxacin (MIC 16 mg/L), while the pradofloxacin MIC of the same isolate 
was only 1 mg/L. This result would be classified as intermediate (Kizerwetter-
Review of the literature 
20 
 
Swida et al., 2016). Kizerwetter-Swida et al. (2016) found nearly complete (35/36 
isolates) cross-resistance between enrofloxacin, ciprofloxacin and pradofloxacin. 
2.6.4 Resistance to aminoglycosides 
Aminoglycosides cause misreading of the genetic code by attaching to the 30S 
subunit of the bacterial ribosome, thus disrupting protein synthesis. These 
antimicrobials are mainly used to treat severe infections caused by Gram-negative 
aerobes and staphylococci (Dowling, 2013a), or in the topical therapy of outer ear 
infections, for example (Sykes, 2013). Aminoglycosides are bactericidal, but 
require parenteral dosing for a systemic effect. There is also concern about their 
nephrotoxic effects, limiting their use (Dowling, 2013a). The primary 
aminoglycoside used in small animals is gentamicin, although amikacin may also 
be used for systemic therapy (Papich, 2012; Sykes, 2013). Topical preparations 
may also contain other aminoglycosides, such as neomycin (Lääketietokeskus, 
2016). Resistance to aminoglycoside among staphylococci is most often mediated 
by modifying enzymes (Ardic et al., 2006). Bacteria may simultaneously carry 
numerous different genes that encode diverse aminoglycoside-modifying 
enzymes (Ardic et al., 2006; Dowling, 2013a). In S. pseudintermedius, insertion 
sequence 256 (IS256) has been associated with resistance to gentamicin and 
amikacin (Casagrande Proietti et al., 2012). The resistance mechanism or type of 
enzyme produced determines the spectrum of resistance. In general, amikacin is 
more tolerant of inactivating enzymes (Dowling, 2013a). 
Resistance to aminoglycosides has been described in several studies. Studies 
regarding gentamicin (the type drug for the group) have revealed that resistance 
among all S. pseudintermedius isolates range between 0% and 29% (Lilenbaum 
et al., 1999; Lilenbaum et al., 1998; Rubin et al., 2011; Vanni et al., 2009; Windahl 
et al., 2015; Youn et al., 2011). Among MRSP isolates, resistance to gentamicin 
has varied between 39% and 100% (Casagrande Proietti et al., 2012; Kjellman et 
al., 2015; Morris et al., 2006; Perreten et al., 2010; Ruscher et al., 2010; Sasaki 
et al., 2007a). Amikacin resistance is less reported among S. pseudintermedius, 
but according to a study by Gold et al. (2014), resistant isolates made up nearly 
18% of studied isolates in 2012. On the other hand, an Italian study by De Lucia 
et al. (2011) found no resistance to the drug. Amikacin resistance among MRSP 
isolates appears to be more common (59%) (Casagrande Proietti et al., 2012). 
2.6.5 Resistance to potentiated sulfonamides 
Sulfonamides and diaminopyrimidines are combined to achieve a bactericidal 
effect by blocking consecutive steps in the folic acid synthesis pathway of bacteria 
(Prescott, 2013b). The combination of sulfamethoxazole and trimetoprim (SXT) 
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is often the one used in susceptibility testing (CLSI, 2013a, b). Sulfonamide— 
trimetoprim combinations are used for a number of different infections in dogs 
and cats (Prescott, 2013b; Sykes, 2013). In addition, these combinations have a 
wide margin of safety, although adverse effects particularly due to sulfonamides 
do occur. Resistance to SXT may be mediated though a number of mechanisms, 
including impairment of drug penetration, production of insensitive enzymes, or 
hyperproduction of PABA (Prescott, 2013b).  
Resistance to SXT among S. pseudintermedius is low to moderate, with 
studies showing 5 to 30 percent of isolates being resistant (Beever et al., 2015; 
Ganiere et al., 2005; Humphries et al., 2016; Priyantha et al., 2016; Rubin et al., 
2011; Windahl et al., 2015). However, high levels of resistance (60 to 97%) have 
been observed in some studies (Casagrande Proietti et al., 2012; Youn et al., 
2011). MRSP isolates are generally more resistant to SXT, with 22% to 100% being 
resistant to the drug (De Lucia et al., 2011; Humphries et al., 2016; Kjellman et 
al., 2015; Sasaki et al., 2007a). Nevertheless, as a British study found, resistance 
levels can even vary immensely between laboratories in the same country (Beever 
et al., 2015). The testing of SXT can be technically difficult, as excess thymine in 
the testing media may lead to excessively high resistance results (CLSI, 2013a, b).  
2.6.6 Resistance to miscellaneous antimicrobials 
Fusidic acid is a lipophilic steroid antibiotic (Dowling, 2013c). In veterinary 
medicine, it is used as topical treatment for pyogranulomatous dermatitis (i.e. hot 
spot), as well as ear and eye infections (Clark et al., 2015; Finnish Food Safety 
Authority and the Faculty of Veterinary Medicine, 2016). Resistance to this 
compound has been less frequently studied, probably at least in part due to the 
lack of Food and Drug Administration (FDA) approved preparations in the United 
States of America (Dowling, 2013c). Additionally, while EUCAST has breakpoints 
for the interpretation of fucidic acid susceptibility, CLSI does not. This makes 
comparison of results more difficult. The Finnish Study Group for Antimicrobial 
Resistance (FiRe) standard used to have interpretation criteria for fusidic acid 
(10-μg disc, cut-off values: S ≥ 24 mm, R ≤ 18 mm), which were based on a study 
by Skov et al. (2001). These have now been replaced by the EUCAST standard 
(cut-off values for fusidic acid S ≥ 24, R < 24). Limited information is available 
also on the resistance mechanism to this drug, although alteration of the 
elongation factor of permeability and enzymatic inactivation have been 
implicated (Turnidge and Collignon, 1999). 
Since the drug is primarily used for topical therapy, some studies, such as that 
by Loeffler et al. (2008) have reported fusidic acid as susceptible, even when 
MICs have been higher than the current EUCAST breakpoints. This seems 
appropriate, as the achievable drug concentrations are significantly higher 
Review of the literature 
22 
 
topically than systemically. It would be inappropriate to directly compare results 
from different studies, as the criteria for susceptible and non-susceptible may 
differ. It is also important to note that no breakpoints have been defined for 
susceptibility testing for local therapy. Loeffler et al. (2008) investigated S. 
pseudintermedius and MRSP isolates from dogs and cats, and found that all 
isolates were probably susceptible to concentrations achievable by topical therapy 
(MIC90 ≤4 mg/L). Vanni et al. (2009) made similar discoveries among S. 
(pseud)intermedius isolates from Italy. Likewise, Clark et al. (2015) found that 
nearly all S. pseudintermedius isolates, regardless of whether they were MRSP, 
were susceptible to fusidic acid concentrations that are achievable using local 
therapy (MIC <16 mg/L). In an Italian study, De Lucia et al.  (2011) did not find 
any fusidic acid resistance among MRSP isolates (n = 48). A Norwegian study 
determined that nearly half of all MRSP isolates were resistant to fusidic acid 
when using the ≥1 mg/L MIC breakpoint for resistance set by EUCAST (EUCAST, 
2017; Norstrom et al., 2009). Available fusidic acid preparations in Finland 
contain 5 (otic) or 10 (ophthalmic) mg/g of fusidic acid (Lääketietokeskus, 2016), 
a concentration that far exceeds the breakpoint set by EUCAST (2017). 
Chloramphenicol, a phenicol antimicrobial, like fucidic acid, is mainly used 
for topical therapy in cases of conjunctivitis (Sykes, 2013). It is rarely used 
systemically in veterinary medicine, but has been suggested as a treatment option 
for MRSP infections, where traditional antimicrobials are found ineffective 
(Frank and Loeffler, 2012; Papich, 2012). The antimicrobial works by binding 
irreversibly to the 50S subunit of the bacterial ribosome, inhibiting protein 
synthesis (Dowling, 2013b). Resistance to chloramphenicol is most commonly 
caused by enzymatic inactivation through acetylation (chloramphenicol 
acetyltransferase, CAT), which prevents the binding of the drug to the ribosomal 
subunit (Dowling, 2013b). One gene encoding for these enzymes, catpC221, has 
been described in representatives of the major European MRSP lineage, ST71 
(Perreten et al., 2010). As such, MRSP isolates representing ST71 from Europe 
are generally not susceptible to chloramphenicol, but their ST68 North American 
counterparts usually are (Perreten et al., 2010). However, a Spanish study did not 
detect chloramphenicol resistance among ST71 isolates (Gomez-Sanz et al., 2011). 
Chloramphenicol resistance among S. pseudintermedius is rather rare as a 
whole. Vanni et al. (2009) reported only 3% of isolates resistant to the drug, while 
Rubin et al. (2011) did not detect any resistance to it. Low resistance (0.9%) was 
also reported in a Canadian study (Priyantha et al., 2016). Among MRSP isolates, 
resistance rates are higher. While investigating the association of amikacin 
resistance to a number of antimicrobials Gold et al. (2014) found that 30% out of 
422 investigated isolates were resistant to chloramphenicol. An Italian study 
reported that 60% of MRSP isolates (n = 48) were chloramphenicol resistant (De 
Lucia et al., 2011). 
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2.7 Screening for MRSP 
As with MRSA carriers in humans (Senn et al., 2016; van Rijen et al., 2009), 
MRSP has the potential to spread via healthy carriers (Bergstrom et al., 2012; van 
Duijkeren et al., 2011b). In humans, MRSA is usually screened for by nasal, 
axillae, and perineal swabs, which are commonly enriched and then plated onto 
selective media (Dodemont et al., 2015; Micheel et al., 2015), or directly analyzed 
using PCR (Huletsky et al., 2004; Wassenberg et al., 2010). The sampling sites 
for MRSP screening in dogs vary somewhat in the literature, but particularly the 
nose, mouth, and perianal region/rectum appear in many. Windahl et al. (2012) 
collected specimens from the nostrils, corner of the mouth, perineum, and 
pharynx of dogs. The results indicated that not all sample sites were positive for 
MRSP, despite the animal being a carrier. They reported that the pharynx, closely 
followed by the perineum, yielded the most MRSP isolations. Beck et al. (2012) 
collected specimens from the nose, rectum, and affected skin, and Hanselman et 
al. (2008) from the nose, axilla, and rectum of dogs. The former study found 
MRSP from both nasal and rectal swabs at the same rate, while the latter only 
found MRSP from nasal swabs. The nose was the sole site sampled in a previous 
study of canine patients by Sasaki et al. (2007a). In a Swedish study, specimens 
were obtained from the mouth, nostril, and perianal region (Bergstrom et al., 
2012). In addition to these, an Australian study also sampled the ear of the animal 
(Bean and Wigmore, 2016). S. (pseud)intermedius may be isolated from the nose, 
mouth, anus, vulva, and skin of dogs (Saijonmaa-Koulumies et al., 1998). Fewer 
studies have been conducted on cats, but in one study on cats entering a 
veterinary teaching hospital, the nose, pharynx, perineum, and possible skin 
lesions were swabbed to detect MRSP carriers (Nienhoff et al., 2011a). 
Most studies in which MRSP screening has been performed have utilized an 
enrichment step to increase the sensitivity of the test (Beck et al., 2012; Gomez-
Sanz et al., 2011; Hanselman et al., 2008; Laarhoven et al., 2011; Morris et al., 
2010; Murphy et al., 2009; Paul et al., 2012; Paul et al., 2011; van Duijkeren et 
al., 2011b; Windahl et al., 2012). This enrichment step is performed either in 
Müller-Hinton (Laarhoven et al., 2011; Paul et al., 2012; Paul et al., 2011), tryptic 
soy (Bergstrom et al., 2012; van Duijkeren et al., 2011b; Windahl et al., 2012), or 
brain-heart infusion broth (Gomez-Sanz et al., 2011), and may or may not contain 
selective agents. Common selective agents include sodium chloride (4–7.5% 
NaCl) (Bergstrom et al., 2012; Gomez-Sanz et al., 2011; Hanselman et al., 2008; 
Laarhoven et al., 2011; Murphy et al., 2009; Paul et al., 2011; van Duijkeren et al., 
2011b; Windahl et al., 2012), aztreonam (Bergstrom et al., 2012; Laarhoven et al., 
2011; van Duijkeren et al., 2011b; Windahl et al., 2012), ceftizoxime (Laarhoven 
et al., 2011; van Duijkeren et al., 2011b), cefoxitin (Bergstrom et al., 2012; 
Windahl et al., 2012), or oxacillin (Morris et al., 2010). 
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No commercial media for the screening of MRSP exist. As commercial media 
for MRSA screening probably contain cefoxitin, a more sensitive predictor of 
MRSA (CLSI, 2013a; Pourmand et al., 2014), the media may contain too much of 
the antimicrobial to allow MRSP with lower MICs to grow. This may result in 
MRSP carriers being missed when using media designated for MRSA, to screen 
for MRSP. The agars used in published studies have often been non-selective if 
the enrichment medium contains antimicrobial agents (van Duijkeren et al., 
2011b; Windahl et al., 2016; Windahl et al., 2012), and vice-versa (Beck et al., 
2012; Gomez-Sanz et al., 2011; Laarhoven et al., 2011; Paul et al., 2011). However, 
some studies have used antimicrobials in both (Morris et al., 2010; Murphy et al., 
2009). Commercial selective agars used include ORSAB (Oxoid) (Gomez-Sanz et 
al., 2011), MRSA Brilliance (Oxoid) (Paul et al., 2011), and BBL CHROMagar 
(Becton, Dickinson & Co.) (Beck et al., 2012). Mannitol-salt agar with oxacillin 
has also been used (Hanselman et al., 2008). 
2.8 Molecular methods used for typing MRSP 
2.8.1 Pulsed-field gel electrophoresis 
Pulsed-field gel electrophoresis (PFGE), described in the mid 1980s (Schwartz 
and Cantor, 1984), is a method for determining the relatedness of microbes by 
using the entire genome to create a genetic fingerprint. The method involves 
cutting the whole genome DNA using macro-restrictive (rare cutting) enzymes. 
Restriction enzymes bind to and cleave specific sites in the genome, and the 
number of bands each isolate generates is dependent upon the number of 
restriction sites. The DNA is digested in blocks of agar to prevent physical 
breakage of the genomic material. The resulting fragments are then separated 
using electrophoresis, where the direction of the current is repeatedly shifted. 
This promotes the separation of bands, as larger bands take longer to realign after 
each switch. The band pattern of the isolate can then be compared to other 
isolates visually, or by computer software. The more bands the isolates have in 
common, the closer the relationship (Tenover et al., 1995). Isolates with identical 
fingerprints (zero band difference) are indistinguishable. If they differ by 2–3 
bands, they are considered closely related. If the difference is 4–6 bands, the 
isolates are possibly related, and if they differ by ≥7 bands, they are considered 
different (Tenover et al., 1995).  PFGE can be used to type a number of bacteria, 
but the methodology varies between species. A harmonized method has been 
published for S. aureus (Murchan et al., 2003), but not for S. pseudintermedius. 
This method has, however, been used, with success, in a plethora of studies 
regarding S. pseudintermedius (Couto et al., 2016; Davis et al., 2014; Feng et al., 
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2012; Gomez-Sanz et al., 2013; Kadlec et al., 2016; Kjellman et al., 2015). Despite 
the method being old and unable to detect many genetic mutations, PFGE is still 
a valuable tool in outbreak investigations and assigning genetic relatedness, as it 
is able to visualize >90% of a genome and is less expensive than whole genome 
sequencing (WGS) approaches (Goering, 2010; MacCannell, 2013). 
2.8.2 Staphylococcal cassette chromosome mec typing 
The mecA gene is located in a staphylococcal chromosomal cassette (SCC). SCCs 
are mobile genetic islands located throughout the staphylococcal genome. These 
sequences have the ability to capture foreign DNA fragments when the 
environment becomes hostile to the bacterial cell. SCCmec is a mobile element in 
which the methicillin resistance gene, as well as other resistance genes, can be 
transferred between bacteria (IWG-SCC, 2017a). The homology between SCCmec 
cassettes is considered an indication of horizontal gene transfer between 
staphylococcal species (Hanssen and Ericson Sollid, 2006). 
At the time of writing, there are eleven recognized SCCmec types (IWG-SCC, 
2017a). As a common characteristic, the SCCmec elements all carry the mecA or 
mecC gene, which encode for the altered surface protein PBP2a (IWG-SCC, 2009; 
Ubukata et al., 1989). SCCmec types are determined by the combination of 
different ccr (cassette chromosome recombinases) and mec gene complexes 
(IWG-SCC, 2009). The mec complex contains the mecA gene, as well as mecR1 
and mecI, which control the expression of mecA. mecR1 encodes a signal 
transducer protein (MecR1) and mecI encodes a repressor protein (MecI) (IWG-
SCC, 2009). The ccr complex consists of the ccr genes: ccrAB and/or ccrC. These 
genes enable the SCCmec element to recombine with the staphylococcal 
chromosome at specific insertion site sequences (ISS). In addition, the SCCmec 
element also contains three “junkyard regions”, or J regions. These are 
nonessential sequences contained within the cassette. The length and order of the 
different components of the cassette vary between different complexes and 
classes. For example, class A mec gene complexes contain mecA, mecR1, and 
mecI, as well as IS431 downstream of mecA, while class B mec gene complexes 
have a truncated mecR1 due to the insertion of IS1272 upstream of mecA. SCCmec 
elements are also classified into various subtypes depending on the composition 
of, for example, the J regions. The description of all differences is beyond the 
scope of this review. The main components of the SCCmec IV are visualized in 
Figure 2. The ccr and mec gene complexes and their corresponding SCCmec types 
are presented in Table 1. 
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Figure 2 The main components of SCCmec IV (2B). orfX, open reading frame X; IS, insertion 
sequence; J, junk region. Adapted from IWG-SCC (2009). 
 
 Table 1 ccr and mec gene complexes and corresponding SCCmec types according to the 
International Working Group on the Staphylococcal Cassette Chromosome elements 
(IWG-SCC). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCCmec typing may be used to assess the mobility of mecA, and the identification 
of the same SCCmec in different strains may indicate the horizontal spread of this 
genetic element. SCCmec analysis can aid in the further characterization of 
staphylococci, and in the control and prevention of spread (Liu et al., 2016). A 
recent study suggested that MRSP isolates carrying SCCmec type II-III could be 
designated as healthcare associated (HA-MRSP), while MRSP stains with 
SCCmec type V could be designated as community associated (CA-MRSP) (Kasai 
et al., 2016). A similar, rough classification has previously been carried out for 
MRSA, where MRSA strains carrying SCCmec type IV are often considered 
SCCmec type ccr gene complex (gene) mec gene complex 
I 1 (A1B1) B 
II 2 (A2B2) A 
III 3 (A3B3) A 
IV 2 (A2B2) B 
V 5 (C1) C2 
VI 4 (A4B4) B 
VII 5 (C1) C1 
VIII 4 (A4B4) A 
IX 1 (A1B1) C2 
X 7 (A1B6) C1 
XI 8 (A1B3) E 
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community associated, while MRSA strains with type III are often considered 
healthcare associated (Liu et al., 2016). 
2.8.3 Multi-locus sequence typing 
Multi-locus sequence typing (MLST) is one of the most valuable methods for long-
term and global epidemiology (Bannoehr and Guardabassi, 2012). In this method, 
specific gene alleles, so-called housekeeping genes, are sequenced and compared 
to database entries of similar sequences (Maiden et al., 1998). These genes are 
essential for the metabolism of the microbe and are thus realitvely stable to 
mutation, which results in a slow evolution and change in the genetic sequence 
(Bannoehr and Guardabassi, 2012). Usually, only an approximately 450 to 500 
base pair (bp) fragment is sequenced for each gene, as this is a length for which 
both DNA strands may be sequenced in their entirety using only one forward and 
one reverse primer (Enright and Spratt, 1999). Each novel sequence in a certain 
allele is assigned a number, and the combination of the numbers for each gene 
allele determines the allelic profile of an isolate, which in turn defines the 
sequence type (ST) (Enright and Spratt, 1999). STs are further grouped into clonal 
complexes (CC) based on the similarity of allelic profiles (i.e. how many allele 
numbers they have in common). Isolates that differ at one locus (SLV, single-
locus variant) or two loci (DLV, double-locus variant) are often grouped into the 
same CC (Damborg et al., 2016; Duim et al., 2016), although official CCs for S. 
pseudintermedius have yet to be assigned (http://pubmlst.org/spseud 
intermedius/). A common way of analyzing genetic relatedness from MLST data 
is eBURST. This method predicts the founding (ancestral) genotype of each clonal 
complex, and computes the bootstrap support for the assignment (Feil et al., 
2004). 
The current method for determining the ST of S. pseudintermedius was 
described by Solyman et al. (2013). In this method, seven different gene loci are 
sequenced: tuf (elongation factor Tu), cpn60 (chaperonin), pta 
(phosphotransacetylase), purA (adenylosuccinate synthetase), fdh (formate 
dehydrogenase), ack (acetate kinase), and sar (sodium sulfate symporter). An 
earlier method, described by Bannoehr et al. (2007), was based on four of these. 
At the time of writing this review, well over 700 described STs exist for S. 
pseudintermedius (http://pubmlst.org/spseudintermedius/). 
2.8.4 spa typing 
spa typing relies on the analysis of tandem repeat sequences of the staphylococcal 
protein A (spa) gene, and more specifically, the sequence variation of region X of 
the gene (Frenay et al., 1996). Moodley et al. (2009) described a method for spa 
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typing of MRSP isolates. The method is not suitable for the typing of MSSP 
isolates, as over 50% of isolates are non-typeable (Bannoehr and Guardabassi, 
2012). It is, however, simpler and less time consuming than MLST or PFGE 
(Bannoehr and Guardabassi, 2012). An online database of identified spa types is 
available at http://www.pse-spa.org/spa-types.html. At the time of writing this 
review, there are over 70 identified spa types for S. pseudintermedius. 
2.8.5 Whole genome sequencing 
The whole genome sequence of S. pseudintermedius was published in 2011 (Ben 
Zakour et al., 2011). However, while whole genome sequencing (WGS) has been 
utilized when investigating the epidemiology of MRSA in humans (Azarian et al., 
2015; Bartels et al., 2015; Ugolotti et al., 2016), its use has been very limited 
regarding MRSP. A study by Windahl et al. (2016) did utilize WGS to investigate 
the relatedness of MRSP isolates from dogs within the same family. Moreover, the 
whole genome sequences of three predominant STs, 71, 68, and 84, have recently 
been published (Riley et al., 2016). It is likely that this method, once more 
affordable, will gradually replace the methods discussed above.  
2.9 The epidemiology and occurrence of MRSP 
In the 1980s methicillin resistance among S. (pseud)intermedius was practically 
unheard of (Medleau et al., 1986; Phillips and Williams, 1984). The earliest 
oxacillin-resistant S. (pseud)intermedius isolates were discovered from healthy 
dogs in the mid-1980s, in France (Pellerin et al., 1998). A decade later, MRSP 
isolates were also being reported in Spain (Piriz et al., 1996), although they were 
still rare as a whole (Gortel et al., 1999). In 1999, it was determined that MRSP 
carried the mecA gene (Gortel et al., 1999). There was, however, an alarming 
increase in methicillin resistance among S. (pseud)intermedius isolates in the 
United States of America in the early 2000s (Bemis et al., 2009; Jones et al., 
2007). Although a French study of clinical isolates from canine pyoderma 
specimens in 2002 did not detect any methicillin resistance among fifty S. 
(pseud)intermedius isolates (Ganiere et al., 2005), MRSP isolates were detected 
in Denmark, Switzerland, and Canada in 2004 (Perreten et al., 2010). The next 
year, the first isolates of multi-resistant, mecA-positive S. (pseud)intermedius 
were detected in Germany (Loeffler et al., 2007). MRSP was then identified in 
twelve cases at a veterinary dermatology referral clinic. This was probably the first 
symptom of the upcoming spread of MRSP ST71 in Europe, which has propagated 
very rapidly since (Perreten et al., 2010). ST71 is typically resistant to, among 
others, beta-lactams, gentamicin, chloramphenicol, trimethoprim, macrolides, 
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lincosamides, tetracycline, and ciprofloxacin (Perreten et al., 2010). It is thus 
resistant to nearly all antimicrobials authorized for veterinary use in Finland 
(Lääketietokeskus, 2016). In the following years, MRSP findings were also 
reported in other European countries: in Sweden, the Netherlands, and Italy 
(Perreten et al., 2010). As a result of the propagation of MRSP, the proportion of 
MRSP isolates among S. pseudintermedius in the United States, for example, 
increased from being negligible (<5%) in the 1990’s (Petersen et al., 2002), to 
>10% in the 2000s (Jones et al., 2007).  
Due to differences in methodologies and the origin of isolates, direct 
comparison of resistance data can be difficult. A Finnish study in the early 2000s 
examined the susceptibility of certain bacteria in dogs that had or had not 
received antimicrobial treatment, but did not find any methicillin-resistant 
staphylococci (Rantala et al., 2004). The first official mecA-positive MRSP 
findings in Finland were in 2005–2006, according to surveillance reports 
published by the Finnish Food Safety Authority Evira (FINRES-Vet, 2007). In all, 
there were three confirmed MRSP isolates among forty-seven studied. More 
current data, as well as data from studies from other regions of the world, have 
been compiled in Table 2. 
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Table 2 The proportion of MRSP among Staphylococcus pseudintermedius isolates or 
prevalence of MRSP in different studies. 
Studies regarding the proportion of MRSP among S. pseudintermedius isolates 
Region % MRSP* n Note Reference 
North America 
  USA 0 197 Skin lesions from dogs (Medleau et al., 1986) 
  USA 17 336  (Morris et al., 2006) 
  USA 16 1317 Year 2005 (Jones et al., 2007) 
  USA 30 1755 Year 2007 (Bemis et al., 2009) 
Asia 
  South China 48 144  (Feng et al., 2012) 
  Northern China 48 69 Isolates from pyoderma (Wang et al., 2012) 
  South Korea 35 178 SIG, from companion 
animals and veterinary 
personnel 
(Youn et al., 2011) 
Europe 
  Italy 21 48 SIG (De Lucia et al., 2011) 
  Poland 12 221 SIG (Chrobak et al., 2011) 
  Germany 8 847 SIG (Ruscher et al., 2009) 
  Portugal 9 446  (Couto et al., 2016) 
  Several 6 605  (Ludwig et al., 2016) 
Nordic countries 
  Sweden 2 393  (SWEDRES-SVARM, 2016) 
  Finland 26 
16 
72 
440 
Year 2009 
Year 2012 
(FINRES-Vet, 2011) 
(FINRES-Vet, 2015) 
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Table 2 cont. 
Prevalence of MRSP in animal populations 
Region % MRSP* n Note Reference 
North and South America 
  Brazil 5 148 Skin surface of healthy cats (Lilenbaum et al., 1998) 
  Brazil 4 150 Saliva of healthy cats (Lilenbaum et al., 1999) 
  USA 0 50 Healthy cats (Abraham et al., 2007) 
  USA 0 48 Cats with inflammatory skin 
disease 
(Abraham et al., 2007) 
  USA 7 59 Dogs with inflamed skin (Griffeth et al., 2008) 
  USA 2 50 Healthy dogs (Griffeth et al., 2008) 
  Canada 2 193 Dogs entering veterinary 
hospital 
(Hanselman et al., 2008) 
  USA 0 200 Healthy cats at an animal 
shelter 
(Gingrich et al., 2011) 
  USA 3 200 Healthy dogs at an animal 
shelter 
(Gingrich et al., 2011) 
  Canada & USA 4 549 Dogs admitted for TPLO 
surgery 
(Nazarali et al., 2015) 
Asia 
  Japan 53 57 SIG, dogs at a veterinary 
hospital 
(Sasaki et al., 2007a) 
  South Korea 26 110 SIG, hospitalized dogs and 
cats 
(Youn et al., 2011) 
Europe 
  Slovenia 1,5 200 Clinically healthy dogs (Vengust et al., 2006) 
  Germany 7 814 Dogs at a veterinary hospital (Nienhoff et al., 2011b) 
  Germany 2 131 Cats at a veterinary hospital (Nienhoff et al., 2011a) 
  Norway 3 189 Healthy dogs at animal clinics (Kjellman et al., 2015) 
Australia 1 117 Healthy dogs in Central 
Victoria 
(Bean and Wigmore, 2016) 
*, Percentages have been rounded; n, number of isolates investigated; SIG, results were reported as 
Staphylococcus intermedius group; TPLO, tibial plateau leveling osteotomy. 
2.9.1 Transmission and carriage of MRSP 
Staphylococci typically cause purulent infections, and the bacteria in the pus are 
easily spread through direct or indirect contact (Caveney et al., 2012; Quinn et al., 
2011). Close contact (i.e. animals in the same family) seems to readily spread 
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MRSP (Laarhoven et al., 2011; van Duijkeren et al., 2011b). Colonized animals 
showing no signs of infection may inadvertently spread the bacteria if they are not 
identified (Laarhoven et al., 2011). 
It is uncertain whether animals can eliminate the bacteria and how long a 
carrier state lasts. One study found that the median length of MRSP carriage was 
11 months when the criterion for clearance was two consecutive negative 
screening specimens (Windahl et al., 2012). However, extended (≥3 weeks) 
antimicrobial therapy may prolong the carrier state (Windahl et al., 2012). 
Laarhoven et al. (2011) followed twelve MRSP-positive dogs for six months with 
monthly sampling, and reported that only two were continuously MRSP positive, 
while five were intermittently positive and four became negative (the criterion for 
this was not specified). The last dog was only positive in the initial sample. For 
MSSP, however, it seems that the bacterium persists in dogs despite attempted 
decolonization therapy (Saijonmaa-Koulumies et al., 1998). 
2.9.2 MRSP in the veterinary environment 
MRSP may spread at veterinary hospitals and clinics. This includes spread in the 
environment, via fomites such as instruments, by veterinary personnel, and by 
colonized and infected patients (Bergstrom et al., 2012; Lehner et al., 2014; van 
Duijkeren et al., 2011b; Youn et al., 2011). S. pseudintermedius can be isolated 
from inanimate surfaces at veterinary facilities (Youn et al., 2011). This was also 
confirmed for MRSP, in a study by Bergström et al. (2012), who isolated MRSP 
on human and animal contact surfaces in the hospital environment. These 
included, among others, the entrance and waiting room floor, light switches, door 
and lamp handles, and taps in the intensive care unit (ICU), isolation ward, and 
dermatology room. The results indicated that the hospital environment was a 
potential source of infection in at least two cases. The study also reported a 
significant increase in the number of dogs that carried MRSP before and after 
surgery and a stay in the hospital, although the change was small (1/45 to 5/45, 
P<0.001). 
Spread via contaminated surfaces is probably facilitated by the ability of S. 
pseudintermedius to form biofilms (Bardiau et al., 2013; Han et al., 2015; Osland 
et al., 2012). A study by Han et al. (2015) found that the vast majority (93.5%) of 
both MSSP and MRSP isolates were strong biofilm producers. Biofilm production 
makes bacteria hardy to cleaning and disinfection, and more resistant to 
antimicrobials (Olsen, 2015), although a clean, dry surface is not a favorable 
environment for biofilm formation (O'Toole et al., 2000). Antimicrobial 
resistance due to biofilm formation was specifically demonstrated for S. 
pseudintermedius by Walker et al. (2016). The authors reported that resistance 
to amikacin, enrofloxacin, cefazolin, and gentamicin was considerably higher 
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(nearly or over 1,000-fold) for both MSSP and MRSP when they were allowed to 
grow in a biofilm. Ferran et al. (2016) also reported high tolerance to 
antimicrobials for S. pseudintermedius in a biofilm. 
2.9.3 MRSP in households 
MRSP is often encountered in the home environment of carrier animals 
(Laarhoven et al., 2011; van Duijkeren et al., 2011b). It has also been shown that 
transmission between an MRSP carrier and another pet in the household is 
common (Laarhoven et al., 2011; van Duijkeren et al., 2011b; Windahl et al., 
2016). Laarhoven et al. (2011) found that contact pets were MRSP positive in six 
out of seven households. In one case, the index dog became MRSP negative during 
follow-up sampling, while the contact animal remained positive. This is contrary 
to what Windahl et al. (2016) found, as contact dogs were only positive if the index 
dog was still positive. 
In a larger study involving twenty households, it was discovered that 36% of 
contact dogs (n = 14) and 31% of contact cats (n = 13) were MRSP positive (van 
Duijkeren et al., 2011b). The study also found that contamination by MRSP of the 
household environment was widespread, as 44% of all environmental specimens 
taken were MRSP positive. 
2.9.4 S. pseudintermedius and MRSP as a zoonosis 
Several studies have determined that S. pseudintermedius can spread from 
animals to humans (Gomez-Sanz et al., 2013; Guardabassi et al., 2004; 
Hanselman et al., 2009; Soedarmanto et al., 2011; van Duijkeren et al., 2008; van 
Duijkeren et al., 2011b). Human colonization with the bacterium is, however, 
considered to be a quite rare, although veterinary professionals may carry it at a 
higher rate than owners (Hanselman et al., 2009; Talan et al., 1989b). One study 
found that the bacterium could be repeatedly identified from the nasal cavity in 
dog owners (Gomez-Sanz et al., 2013). However, as humans are not the 
predominant hosts of S. pseudintermedius, it seems that the period of 
colonization in humans is relatively short (Guardabassi et al., 2004; Paul et al., 
2011), although long-term studies are lacking. 
S. (pseud)intermedius has also been identified as a cause of bite wound 
infections for nearly two decades (Lee, 1994; Talan et al., 1989a). The bacterium 
can also cause deep infections in humans, as was reported by van Hoovels et al. 
(2006), who isolated the bacterium from an infection involving an implantable 
cardioverter-defibrillator. S. (pseud)intermedius has also been reported as a 
cause of bacteremia (Vandenesch et al., 1995), a brain abscess (Atalay et al., 
2005), and pneumonia (Gerstadt et al., 1999) in people. MRSP ST71 has 
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additionally been reported as a cause of human infections in a small, four-patient 
cluster at a tertiary care hospital in Sweden (Starlander et al., 2014). While no 
animal source was identified in these cases, humans with an infection caused by 
S. pseudintermedius commonly have canine contacts (Lozano et al., 2017; 
Somayaji et al., 2016).  
In the case described by van Hoovels et al. (2006), S. pseudintermedius had 
originally been misidentified as S. aureus. This is not an isolated case of 
misidentification, as was shown by Börjesson et al. (2014). Their study concluded 
that 13% of the S. aureus isolates retrieved from dog bite wounds in humans had 
been misdiagnosed, and were in fact S. pseudintermedius. One of these carried 
the mecA-gene, i.e. was MRSP. 
Human cases of MRSP colonization and infection are less reported. 
Hanselman et al. (2009) found that 0.4% of humans (n = 242) living in the same 
household as a dog or cat carried MRSP. Veterinary professionals are also 
exposed to MRSP and are thus at risk of being colonized or infected by it 
(Guardabassi et al., 2004; Morris et al., 2010; Paul et al., 2011). 
In addition to the direct spread of the bacteria, the horizontal spread of 
resistance genes via the spread of mobile genetic elements (e.g. SCCmec) into 
human pathogens is also a concern. While there is no direct evidence of SCCmec 
elements transferring between S. pseudintermedius and, for instance, S. aureus, 
studies have shown significant homology between these genes among other 
staphylococci, i.e. Staphylococcus epidermidis, S. scuiri, and S. haemolyticus 
(Hanssen and Ericson Sollid, 2006; Hanssen et al., 2005; Hanssen et al., 2004; 
Wisplinghoff et al., 2003). It is therefore reasonable to consider that the transfer 
of resistance genes is possible (Guardabassi et al., 2004). 
2.9.5 Molecular epidemiology of MRSP 
The molecular epidemiology of MRSP has recently been reviewed (Pires Dos 
Santos et al., 2016). An international study by Perreten et al. (2010) investigated 
the genetic characteristics of MRSP isolates from the United States (California, 
North Carolina, and Tennesee), Canada (Ontario), as well as several European 
countries (Denmark, Germany, Italy, the Netherlands, Sweden, and Switzerland). 
The study found that the MRSP population had spread clonally on both sides of 
the Atlantic Ocean. ST68 was the most frequent ST among isolates from North 
America, while ST71 had established itself as the most common clone among 
European isolates. Since then, ST71 has also been described as a major clone in 
Japan (Bardiau et al., 2013) and China (Boost et al., 2011; Wang et al., 2012). 
SCCmec II-III is almost exclusively carried by CC71 isolates (Couto et al., 2014; 
Ishihara et al., 2016; Perreten et al., 2010). While ST68 and related isolates 
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(CC68) are still most common in North America, one-third of isolates belonging 
to this CC originate in Europe (Pires Dos Santos et al., 2016). 
In recent years, studies have indicated a change in the population structure of 
MRSP in several countries. Reports from Sweden (SWEDRES-SVARM, 2015, 
2016), Denmark (Damborg et al., 2016), and the Netherlands (Duim et al., 2016) 
all indicate that ST71 is being displaced by a more heterogeneous MRSP 
population. However, isolates belonging to CC258 (i.e. ST258 and related clones) 
have become more common since 2010 (Damborg et al., 2016; Duim et al., 2016; 
SWEDRES-SVARM, 2016). This CC has been predominantly identified in MRSP 
clones from Europe (98%) (Pires Dos Santos et al., 2016). Nevertheless, the 
SWEDRES-SVARM report, as well as the studies by Duim et al. (2016) and 
Damborg et al. (2016), also describe a plethora of other STs in the MRSP 
population. While SCCmec IV is widely described among CC258 isolates 
(Damborg et al., 2016), it has also been described in other, unrelated STs, such as 
ST268 and 286 (Damborg et al., 2016), and ST106 (Paul et al., 2011). This 
SCCmec type has even been confirmed to spread between staphylococcal species 
(Smyth et al., 2011). It has also been indicated that the fitness cost of carrying this 
SCCmec type is negligible (Lee et al., 2007). Other SCCmec types also appear to 
be associated with specific CCs. SCCmec type II-III is predominantly found in 
CC71 isolates (Perreten et al., 2010). This SCCmec type is the result of a 
combination of SCCmec II (from S. epidermidis) and SCCmec III (from S. aureus) 
(Descloux et al., 2008). Furthermore, SCCmec type V has been associated with 
CC68, CC45, and CC379 (Pires Dos Santos et al., 2016). 
Another common worldwide clone is CC45 (i.e. ST45 and its related strains 
e.g. ST83, 113, 179 etc.). Members of this CC have been detected in Europe 
(Damborg et al., 2016; Duim et al., 2016; SWEDRES-SVARM, 2016), the Middle 
East and Asia (Perreten et al., 2013), and Australia (Siak et al., 2014). 
Interestingly, a Norwegian study did not find any CC45 isolates (Kjellman et al., 
2015). CC45 isolates are commonly non-typeable by SmaI PFGE and common 
SCCmec methods. Isolates belonging to this CC generally carry a pseudo-SCCmec 
element (ΨSCCmec57395), which was described by Perreten et al. (2013). 
2.10 Risk factors for MRSP 
Several studies have investigated potential risk factors for MRSP. Studies can be 
roughly divided into those that have investigated risk factors for an animal to be 
an MRSP carrier (Beck et al., 2012; Hanselman et al., 2009; Nazarali et al., 2015; 
Nienhoff et al., 2011b; Windahl et al., 2012), and those that have investigated the 
risk factors for an S. pseudintermedius isolate to be MRSP (Eckholm et al., 2013; 
Huerta et al., 2011; Kasai et al., 2016; Lehner et al., 2014). 
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For carriage of MRSP, important risk factors are former hospitalization and 
antimicrobial therapy (Nienhoff et al., 2011b). It has also been proposed that 
antimicrobial therapy prolongs the carriage of MRSP (Windahl et al., 2012). A 
Canadian study by Beck et al. (2012) found that dogs that had previously given 
negative screening specimens for MRSP had an increased risk of acquiring MRSP 
if they had been treated with clindamycin. The same study also concluded that 
MRSP acquisition during treatment of pyoderma seemed to be common (8% pre-
treatment vs. 27% post-treatment), and that the prevalence of MRSP among 
dermatological patients was high (40.5% of skin cultures, 34.1% of screening 
specimens among 173 dogs). Among dogs and cats, the former appear to carry 
MRSP at a higher rate, (Hanselman et al., 2009; Nienhoff et al., 2011a; Nienhoff 
et al., 2011b; Ruscher et al., 2009). Dogs therefore also more commonly have an 
infection caused by MRSP (Kadlec et al., 2010; Morris et al., 2006). A study by 
Lehner et al. (2014) that compared the signalment and medical data of 150 MRSP 
cases to 133 MSSP controls did, however, find indications that being a cat may be 
a risk factor for MRSP. The number of cats in the control group was nevertheless 
too small to draw a decisive conclusion. 
Antimicrobial therapy has also been indicated as a risk factor for an S. 
pseudintermedius isolate being MRSP (Eckholm et al., 2013; Huerta et al., 2011; 
Kasai et al., 2016; Lehner et al., 2014). Kasai et al. (2016) investigated 282 clinical 
S. pseudintermedius isolates from 462 dogs in Japan. The study revealed that 
antimicrobial therapy in general, and treatment with beta-lactams (including 
cephalexin, and third-generation cephalosporins), was a risk factor for the isolate 
being MRSP (vs. MSSP). Furthermore, they found that treatment with 
fluoroquinolones, topical treatment with mupirocin, the number of 
antimicrobials, underlying disease, age, and hospitalization and surgery 
increased the risk of MRSP. Previous hospitalization or repeated veterinary visits 
have also been implicated as risk factors for MRSP (vs. MSSP) (Eckholm et al., 
2013; Lehner et al., 2014). 
Furthermore, other sporadic risk factors have been identified. Huerta et al. 
(2011), when investigating risk factors associated with resistance in staphylococci 
in general, reported that animals residing in rural areas were at higher risk of 
having MRSP. In addition, systemic glucocorticoid therapy was reported as a risk 
factor by Nienhoff et al. (2011b). This was, however, probably attributable to other 
associated factors, such as frequent veterinary visits or antimicrobial therapy. The 
findings of Lehner et al. (2014) were similar, as glucocorticoid therapy was a 
significant risk factor. A study by Beck et al. (2012) did, however, propose the 
opposite, as glucocorticoid or cyclosporine therapy tended to decrease the 
likelihood of MRSP. Concerning surgical site infections (SSI) caused by MRSP, 
Nazarali et al. (2015) investigated the probability of an SSI caused by MRSP and 
other bacteria after TPLO surgery among MRSP carriers and non-carriers. 
Interestingly, the study concluded that bulldogs were at a higher risk of SSI by 
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either MRSP or any other pathogen within 30 days after TPLO surgery. 
Furthermore, the study found that postoperative antimicrobial administration 
was a protective factor against SSIs. The same effect was shown for orthopedic 
surgeries in general in a study by Pratesi et al. (2015). They noted that dogs 
receiving postoperative cephalexin or potentiated amoxicillin developed an SSI in 
4% of cases (n ~ 50), while animals that did not receive antimicrobials after 
surgery developed SSIs in 21% of cases (n = 47). The study did not investigate the 
probability of developing resistance due to the therapy. However, in human 
medicine, postoperative use of antimicrobials to prevent SSIs is not 
recommended by the World Health Organization (WHO), as there is evidence 
that such measures are not necessary to prevent SSIs (Kang et al., 2009; 
Khariwala et al., 2016; Lopez and Molina, 2015; WHO, 2016).
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3 Aims of the study 
The aims of this study were to: 
 
1. Determine the prevalence of MRSP; 
2. Investigate the epidemiology of and risk factors for MRSP; 
3. Study the molecular epidemiology of MRSP in Finland and how it has 
changed over time; and 
4. Investigate the antimicrobial susceptibility trends of Staphylococcus 
pseudintermedius in Finland
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4 Materials and methods 
4.1 Study setting 
This study was conducted at the Clinical Microbiology Laboratory (CML) of the 
Faculty of Veterinary Medicine, University of Helsinki. The CML provides 
bacteriological analysis services to the University of Helsinki Veterinary Teaching 
Hospital (VTH) and private veterinary clinics and veterinarians throughout 
Finland. The study utilized data and isolates of the CML database and strain 
collection, as well as specimen information stored in the laboratory information 
system and the VTH patient information system. In 2011–2015, the laboratory 
processed 19,249 microbiological specimens, of which 6889 (32%) were pus 
specimens, 5990 (28%) were urine specimens, 3573 (17%) were from 
miscellaneous sources (respiratory, fecal etc.) and 514 (2%) were blood cultures. 
The rest, 4296 (20%), were specimens for screening of resistant bacteria (MRSP, 
MRSA or ESBL), predominantly collected from animals with risk factors. The 
majority (67%) of the specimens were from the VTH, while the rest were from 
private veterinary clinics. Apart from the investigation of clinical specimens, the 
laboratory is responsible for resistance surveillance of small animal pathogens in 
the hospital and in Finland. 
For study I, the risk factors for MRSP during an MRSP outbreak at the VTH 
were studied among hospitalized patients of the VTH. The VTH is a national 
primary care and referral animal hospital in Finland. The hospital provides 24/7 
emergency and intensive care services primarily for animals in the Greater 
Helsinki area. The Small Animal Hospital of the unit has approximately 18 000 
visits annually, with nearly 2000 surgical procedures. Approximately 80% of 
patients are dogs, 17% cats, and the rest are other species. 
In study II, the prevalence of MRSP and MRSA, as well as risk factors for these, 
were studied amongst the guide dog population of the Guide Dog School (GDS) 
of the Finnish Federation of the Visually Impaired. The school is a nonprofit 
organization whose mission is to enhance the independence of people who are 
blind or visually impaired through the use of specially trained dogs, and is 
situated in the greater Helsinki area in Finland 
(http://opaskoirakoulu.fi/?lang=en). The school breeds the majority of their dogs 
themselves, and breeding bitches are housed in volunteer families. The bitches 
give birth at the GDS facilities in a separate ward reserved for this purpose. 
Puppies spend their first six weeks with their dam at the school, after which they 
are weaned and housed in volunteer families. During the first year of their life, 
the dogs have regular (short) appointments at the school. At the age of 13–18 
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months, guide dog candidates are transferred back to the school, where they 
undergo suitability testing. If selected, the dog begins a training period of 20 
weeks, after which it is placed for service as a guide dog. During their service, the 
dogs spend short periods at the school in training; the GDS facilities also serve as 
a kennel for guide dogs during vacations of their host or hostess. 
This study was undertaken because in 2012–2013, MRSP was discovered in 
routine clinical specimens from three GDS dogs with atopic dermatitis. The dogs 
of the GDS constitute a special group of animals; they are in close contact during 
training at the GDS kennel, after which they are sent all over the country. During 
their service years, they also regularly visit the school’s premises. Thus, the 
nationwide risk for the spread of resistant bacteria is a valid concern. At the time 
the study was planned, the size of the guide dog population was approximately 
330 dogs. Out of these, roughly 110 dogs were in training, 200 worked as guide 
dogs, and 20 animals were breeding bitches. 
For study III, bacterial isolates for susceptibility data originated from clinical 
and screening specimens that had arrived to the CML in 2011–2015. To 
investigate the molecular epidemiology of MRSP, all MRSP isolates stored at the 
CML in 2010–2014 were used. 
4.2 Specimen collection (I–III) 
Clinical specimens (i.e. specimens from infection sites, such as wounds, 
abscesses, and peritoneal fluid) were collected by the treating veterinarian. 
Specimens from open lesions were largely retrieved by swabbing the lesions with 
a sterile swab with transport medium (M40 Transsystem Amies Agar Gel, with or 
without charcoal, Copan Diagnostics Inc., Italy). Specimens from deep closed 
lesions (synovial fluid, abscesses, etc.) were mainly collected into a transport vial 
(Port-F, Biomerieux, France). 
Screening specimens from dogs and cats were collected by swabbing (as 
above) the mucous membranes of the nose and mouth of the animal, as well as 
the perineum. If the animal had any skin lesions, these were also swabbed. 
Patients screened for MRSP commonly have identified risk factors for MRSP, 
such as frequent antimicrobial exposure, chronic or intermittent infection, such 
as pyoderma, surgical site infection, or previous exposure to MRSP (either in 
hospital or family). 
Clinical specimens may have revealed any bacteria that were capable of growth 
on standard media (see section 4.3), while screening specimens could only reveal 
MRSP or MRSA. 
Screening specimens for study II were collected between February and 
November 2014, when the dogs visited the GDS. This method was selected out of 
convenience instead of random sampling. Additionally, dogs in the same family 
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of MRSP-positive guide dogs were also screened for MRSP. The specimens in this 
study were then transferred to the CML, where they were kept refrigerated at 
+4°C if they arrived outside office hours. All specimens were processed within two 
days of sampling. 
4.3 Bacteriological culture (I–III) 
Specimens were cultured according to the standard methods of the laboratory. In 
short, specimens from superficial lesions were cultured onto a blood agar plate 
(Tryptone Soy Agar with 5% Sheep Blood, Oxoid, Germany), as well as an 
assortment of different selective and non-selective agars, depending on the 
specified specimen site. Specimens from deep open and closed lesions were 
additionally cultured anaerobically using at least a fastidious anaerobe agar with 
5% horse blood (Oxoid, Germany). These specimens were also placed in an 
enrichment broth (Fastidious Anaerobe Broth, Tammer-Tutkan Maljat Oy, 
Finland) to increase the sensitivity to detect bacterial growth. 
Screening specimens were cultured by pooling all swabs taken from one 
animal (2–3 swabs) into a tryptic soy broth supplemented with 6.5% NaCl 
(Tammer-Tutkan Maljat, Finland). After overnight incubation, an aliquot was 
plated onto an MRSA-selective agar (MRSA Select, BioRad, USA). Plates were 
inspected for typical growth (MRSA: red-pink colonies; MRSP: light-pink 
colonies) after 24 and 48 hours. If typical growth was observed, colonies were 
pure cultured onto blood agar plates. 
4.4 Species identification (I–III) 
Presumptive identification of S. pseudintermedius was based on the typical 
colony morphology and hemolysis pattern (double hemolysis, with complete 
hemolysis [α-toxin] below and near the colony and incomplete hemolysis [β-
toxin] further out), a positive tube rabbit plasma coagulation test (BBL Coagulase 
Plasma, Becton Dickinson, USA), and susceptibility to polymyxin B (300 U, Oxoid 
Ltd, UK) (sensitive ≥10 mm, resistant <10 mm), acid formation from trehalose 
and sucrose (Diatabs, Rosco Diagnostica A/S, Denmark), and the source animal’s 
species (canine and feline isolates more likely to be S. pseudintermedius) 
(Devriese et al., 2009; Devriese et al., 2005). If in doubt, testing was expanded to 
maltose and xylose sugars and/or Staph ID32 (bioMérieux SA, France). If an 
isolate did not meet all these criteria, it was characterized as SIG and was omitted 
from the study. Molecular typing methods for MRSP isolates were also utilized to 
definitively confirm the species. 
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4.5 Susceptibility testing (I–III) 
Susceptibility testing for all studies was performed using the disk diffusion 
method (Oxoid Ltd., UK) in accordance with the Clinical and Laboratory 
Standards Institute (CLSI) performance standards (CLSI, 2013a, b). All 
breakpoints were derived from this standard, except for the breakpoint for fusidic 
acid, which was derived from the FiRe standard (version 6) (National Institute of 
Health and Welfare, 2009). Furthermore, a nitrocefin disc test was used (BBL 
Cefinase Paper Disc, Becton, Dickinson & co., USA) to determine wheather an 
isolate produced beta-lactamase. The disk was applied to the zone edge 
surrounding the oxacillin disk on Müller-Hinton agar (CLSI, 2013a, b). The type 
strain Staphylococcus aureus ATCC® 25923™ was used as a control for 
susceptibility testing. 
4.6 Study populations and data collection 
4.6.1 Study I 
The purpose of this study was to describe the MRSP hospital outbreak at the VTH 
and determine the risk factors for acquiring MRSP during the outbreak. The study 
population consisted of dogs and cats that had been hospitalized for 1 day or more 
at the VTH during the outbreak period (November 2010 to January 2012), and 
were thus potentially exposed to nosocomial MRSP. Cases were divided into 
either colonized (MRSP cultured only from mucous membranes) or infected 
(MRSP cultured from an infection site) with MRSP displaying the outbreak 
antibiogram; resistance to oxacillin, erythromycin, clindamycin, 
sulfamethoxazole-trimethoprim, gentamicin, tetracycline, and enrofloxacin, and 
susceptibility to fusidic acid and amikacin. Only infections detected during the 
outbreak period, either after surgical procedures performed at the hospital or 
other infections that appeared after prolonged or several treatment periods in the 
hospital, were included, in order to exclude community-acquired MRSPs. 
Colonized patients were enrolled if the MRSP was detected after at least 1 day of 
hospitalization and the animal had been treated in the same wards as MRSP-
positive patients. Controls were patients from the same population as cases, but 
were negative in MRSP screening. Patients with a positive MRSP specimen on 
first admission and non-hospitalized (policlinic) patients were excluded from the 
study. Data on several potential risk factor variables were collected for all 
included patients (Table 3). 
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Table 3  Risk factor variables analyzed from cases and controls during the MRSP outbreak at 
the Veterinary Teaching Hospital of Helsinki University in 2010–2011. 
Species (dog/cat) Emergency surgery (during 
weekend/evening/night) 
Aminopenicillin medication 
given 
Age (years) Length of anesthesia (min) bDays of aminopenicillin 
therapy 
Gender bDays in hospital Cephalosporin medication 
given 
Breed bDays in surgery ward bDays of cephalosporin 
therapy 
Weight (kg) bDays in intensive care unit cEnrofloxacin medication given 
aSeverity of condition bDays in other wards bDays of enrofloxacin therapy 
Skin lesions of any cause Antimicrobial medication given Proton pump inhibitor (PPI) 
given 
Surgical procedure bDays of any antimicrobial 
therapy 
bDays of PPI therapy 
a, Severity was assessed by the author (TG) on a scale of 1 to 5 after reviewing the patient record on 
admission and was based on the guidelines provided by the American Society of Anesthesiologists. 
b, The same patient might have had several visits or courses of medication. Therefore, the cumulative 
number of days for these variables was recorded until the first positive MRSP specimen (cases), or 
latest negative MRSP specimen (controls); see text for details. c, Enrofloxacin was the only 
fluoroquinolone used for these patients. 
4.6.2 Study II 
This study was undertaken to determine the prevalence of MRSP and MRSA at 
the GDS and identify risk factors for an animal carrying MRSP. The sample 
population consisted of guide dogs that visited the GDS (a convenience sample), 
while the target population was all dogs of the GDS. To identify possible risk 
factors for MRSP, the following data were collected from the dogs of the sample 
population: breed, sex, age, whether the animal was bred by the GDS or 
purchased, whether it was a trainee, at service or a breeding bitch, and medical 
history. Medical history included information on previous skin disease, and 
antimicrobial and other medical treatments within a 12-month period prior to 
entering the study. The age, sex, breed, and dog group variables, as well as the 
exact number of dogs in the whole population, and different subgroups were 
collected from the entire target population, in order to assess the 
representativeness of the sample population. 
4.6.3 Study III 
For the analysis of antimicrobial susceptibility and yearly trends in antimicrobial 
resistance, results for all clinical isolates identified as S. pseudintermedius 
between June 2011 and the end of 2015 at the CML were compiled from the 
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laboratory information system (LIS) (Provet Net, Finnish Net Solutions, Finland). 
This time period was selected to ensure consistent data, as an overhaul of the LIS 
was carried out in May 2011. Isolates originated from both the VTH as well as 
private veterinary clinics and were identified from either clinical specimens or 
screening specimens. In addition, patient information data were collected on the 
species, sex, specimen type, presence of antimicrobial therapy at the time of 
sampling, and submitting clinic. Antimicrobials tested in the basic panel included 
clindamycin, erythromycin, fucidic acid, oxacillin, 
sulfamethoxazole/trimetoprim and tetracycline. Comparable data for the 
extended panel (amikacin, chloramphenicol, doxycycline, enrofloxacin, and 
gentamicin) were only available for 2015. Denominator data on the numbers of 
specimens per time period were also extracted from the LIS. MRSP isolates stored 
in 2010–2014 were used for molecular analysis. 
4.6.4 Unpublished data 
To determine the incidence and distribution of MRSP in Finland, specimen and 
denominator data from study III were used to calculate the incidence of MRSP in 
clinical specimens. To determine the distribution of MRSP in Finland, the 
geographic origin of a specimen in study III was assigned according to the postal 
address zip codes of the submitting clinic. These were then grouped according to 
the jurisdictional regions of the six Regional State Administrative Agencies 
(referred to only as regions) of continental Finland. 
Furthermore, oxacillin susceptibility histograms and the production of 
beta-lactamase among S. pseudintermedius isolates were investigated. Data on 
susceptibility histograms for oxacillin in 2011 and 2015 were collected from 
WHONET using the same data as in study III. For the production of beta-
lactamase, consistent laboratory data were only available for the year 2016. 
4.7 Data analysis and statistical methods 
All statistical analyses for studies I and II were performed using the SAS System 
for Windows, version 9.3 (SAS Institute Inc., USA). For study III, statistical 
analyses were performed with SAS (as above) to compare the differences in 
resistance between MRSP and MSSP, as well as time-trend analyses, and using 
SPSS version 24 (IBM Inc., USA) for risk factor analyses. P-values <0.05 were 
considered statistically significant in all studies. 
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4.7.1 Study I 
Descriptive analysis of cases related to the outbreak was performed by presenting 
the number of new cases per week over the outbreak and follow-up periods in the 
epidemic curve, along with the implemented control measures. The number of 
colonized and infected patients was recorded. The attack rate was determined by 
using the number of hospitalized patients as the denominator. The risk factors for 
acquiring MRSP were assessed by logistic regression among 55 cases and 213 
controls. Each factor was first modeled using a univariable logistic regression 
model. To control for confounders, a stepwise multivariable logistic regression 
analysis was conducted for the risk factors with a P-value ≤0.05 in the univariate 
analyses. In the stepwise selection process, a significance level of 0.15 was 
required to allow a variable into the multivariable model, and a significance level 
of 0.20 was required for a variable to remain in the multivariable model. Odds 
ratios (OR) with 95% confidence intervals (CI) were calculated. 
4.7.2 Study II 
The sample size for the entire 330-dog population was calculated using EpiTools 
(AusVet-a). The estimated sample size was 152 dogs with an approximated MRSP 
prevalence of 3%, with a ±2% desired precision at a 95% confidence level. The 
guide dogs were considered a low-risk population, and the three percent estimate 
was thus based on previous studies that were considered to represent our target 
population. These showed a prevalence between 1.5 and 4.5 percent (Gingrich et 
al., 2011; Griffeth et al., 2008; Hanselman et al., 2008; Hanselman et al., 2009; 
Vengust et al., 2006). It was not considered necessary to calculate the sample size 
for MRSA separately, since the prevalence of MRSA was expected to be less than 
that of MRSP. 
The prevalence estimates for MRSP and MRSA were calculated as the number 
of positive specimens divided by the total number of collected specimens and 
presented as percentages. The 95% confidence intervals (95% CI) for the 
prevalence estimates were determined using an EpiTools calculator (AusVet-b). 
Confidence intervals were reported based on the Wilson score interval due to the 
low prevalence (Brown et al., 2001). The representativeness of the sample 
population was assessed by using the Fisher’s exact test for sex, breed, and dog 
group, and using an independent two-sample t-test for age. 
Descriptive statistics for the studied variables were calculated according to the 
MRSP status using univariable logistic regression models. Due to very few 
positive MRSP results in the data, the rareness of the events was taken into 
account in the modeling by applying Firth’s bias adjustment method (Firth, 1993), 
which maximizes a penalized likelihood function, instead of the standard 
maximum likelihood function. Odds ratios (OR) with 95% profile likelihood 
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(Venzon and Moolgavkar, 1988) confidence intervals (CI) were calculated to 
quantify the results. 
4.7.3 Study III 
Susceptibility data for clinical S. pseudintermedius isolates (screening specimens 
excluded) were analyzed using WHONET (v. 5.6, WHO). Non-susceptibility 
percentages, including resistant and intermediate isolates, with 95% confidence 
intervals (CI95%) were separately calculated and presented for MRSP, MSSP 
(methicillin-susceptible S. pseudintermedius) and all S. pseudintermedius 
isolates. CLSI breakpoints were used (CLSI, 2013a, b), except for fusidic acid, for 
which a non-susceptibility breakpoint of ≤23 mm was used (National Institute of 
Health and Welfare, 2009). Yearly trends for non-susceptibility percentages were 
plotted and trends were investigated using a Cochran-Armitage trend test for each 
antimicrobial. The statistical difference in non-susceptibilities between MRSP 
and MSSP was investigated using Pearson’s chi-squared test based on the 
WHONET output. To calculate the number of MDR isolates (resistance to ≥3 
antimicrobial classes), macrolide and lincosamide resistance was pooled due to 
common MLSB resistance (macrolide, lincosamide, and streptogramin B) 
(Giguère, 2013a). 
The proportions of MRSP in clinical and screening specimens were calculated 
for dogs and cats in order to derive crude prevalence estimates for MRSP in dogs 
and cats seeking veterinary care, from which microbiological specimens are 
obtained, and in high-risk populations, respectively. 
For the analysis of predictors of MRSP, data were separately analyzed for 
clinical S. pseudintermedius isolates and screening specimens by logistic 
regression with MRSP as the outcome variable. As data from the MRSP outbreak 
at the VTH in 2010–2011 were likely to skew the results, data from this period 
were omitted. Due to the low number of cats in the data (n = 18 for clinical 
specimens and zero positive out of 145 for screening specimens), these, as well as 
specimens from unknown species (n = 11), were omitted from the analyses. OR 
with CI95% and P-values were calculated for each variable. Variables with a P-
value ≤0.2 in the univariable analysis were included in the multivariable analysis. 
Multivariable logistic regression was performed using a backward step (Wald) 
method. 
To compare the genetic relatedness MRSP isolates, the allele sequences for 
each ST were added back-to-back (ack, cpn60, fdh, pta, purA, sar, tuf). The 
resulting sequences were aligned and a phylogenetic tree was inferred by the 
Bayesian Markov chain Monte Carlo method implemented in BEAST (v. 1.7.2) 
(Drummond and Rambaut, 2007). Each run was continued until the effective 
sample size was over 200. Posterior probabilities were calculated with a 10% 
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burn-in, and values >0.7 were considered significant. Results were visualized in 
FigTree (v. 1.40). Additionally, goeBURST (v 1.2.1, http://www.phyloviz.net/ 
goeburst/) software was used for population structure analysis of STs (Francisco 
et al., 2012). Analysis was conducted at double- and triple-locus variant levels. 
Single- and double-locus variants of previously described CCs were assigned to 
that CC (Duim et al., 2016). The number of isolates per ST or CC per year was 
calculated based on the specimen collection date. 
4.7.4 Unpublished data 
The yearly incidence of MRSP among 1000 clinical specimens (regardless of 
whether they revealed S. pseudintermedius) was calculated as a total value, and 
for canine and feline specimens separately. The results were plotted in a graph. 
To assess any change in the distribution of susceptibility, the distribution of 
the zones of inhibition (ZOI) for oxacillin in 2011 and 2015 was visualized as a 
histogram using WHONET. To assess the proportion of MSSP isolates that 
produce beta-lactamase, laboratory output data were placed in Excel (v. 15, 
Microsoft Corporation, USA) and the proportion of beta-lactamase-producing 
MSSP isolates was calculated. The confidence interval for the proportion was 
calculated using EpiTools (AusVet-c, 2017). 
4.8 Molecular methods 
4.8.1 Extraction of genomic DNA 
Bacterial DNA for mecA PCR, SCCmec, and MLST typing was extracted by boiling 
(Alexopoulou et al., 2006) in study I, and with a commercial kit (InstaGene 
Matrix, Bio-Rad, USA) as described previously (DTU Food - National Food 
Institute, 2012) in studies II and III. 
4.8.2 mecA PCR (I–III) 
For study I, MRSP isolates were sent to the Finnish Food Safety Authority (Evira) 
for verification of the presence of mecA (Murakami et al., 1991). For studies II and 
III, the presence of the mecA gene was confirmed using PCR primers (mecA P4 
and mecA P7, see Table 4) described by Stegger et al. (2012). Both primers had a 
concentration of 0.25 μM in a final reaction volume of 20 μl. The PCR was 
performed with a BioRad CFX96 Real-Time PCR detection system in a BioRad 
C1000 Touch thermal cycler using SsoAdvanced Universal SYBR Green Supermix 
(Bio-Rad, USA). The protocol included an initial denaturation at 98.0 °C for 2 
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min, followed by 40 cycles of denaturation (98.0°C for 5 s) and 
annealing/elongation (60.0°C for 45 s). Finally, a denaturation step (98.0 °C for 
5 s) preceded the melt-curve analysis (65.0 °C to 95.0 °C in 0.5 °C increments), 
which was used to verify the product. The product had a melting point of 77.5–
78.0 °C. Staphylococcus aureus ATCC® 43300™ was used as a positive control 
for mecA testing. 
4.8.3 SCCmec typing (I–III) 
The SCCmec cassettes were typed using a previously described multiplex PCR 
method (Kondo et al., 2007) in study I, while the following modifications were 
made for studies II and III: in M-PCR-1, primers γR and γF had a final 
concentration of 0.3 μM, while all other primers in M-PCR-1 and M-PCR-2 had a 
final concentration of 0.2 μM. Primers are presented in Table 4. The PCRs were 
performed with Phire Green HotStart II DNA polymerase (Thermo Scientific, 
USA) with 200 μM of each dNTP in a reaction, or with Phire Green Hot Start II 
PCR Master Mix (Thermo Scientific, USA). The conditions for the PCRs were as 
follows: initial denaturation at 98.0 °C for 1 min, followed by 40 cycles of 
denaturation (98.0 °C for 15 s), annealing (56.0 °C for 10 s) and elongation      
(72.0 °C for 45 s), and a final elongation for 2 min at 72.0 °C. Bands were 
visualized using SYBR Safe DNA stain (Life Technologies, USA) after 
electrophoresis in 1% agarose. The following strains were used for positive 
controls in SCCmec testing: S. aureus NCTC 10442 (I), S. aureus ATCC® BAA-
1720™ (II), S. aureus ATCC® BAA-43™ (III), S. aureus JCSC 6944 (V), and S. 
aureus ATCC® BAA-42™ (VI). 
4.8.4 Multi-locus sequence typing (I–III) 
Multi-locus sequence typing was performed as described by Solyman et al. (2013) 
for study I. For studies II and III, some modifications were made: Phusion Flash 
High-Fidelity PCR Master Mix (Thermo Scientific, USA) was used for the 
reaction. Furthermore, the tuf primers had a final concentration of 0.375 µM 
each, while all other primers had a concentration of 0.25 µM. The PCR protocol 
consisted of a 15- s initial denaturation at 98 °C, 30 cycles of denaturation (98 °C 
for 2 s), annealing (52 °C for 10 s), and elongation (72 °C for 15 s), with final 
extension for 1 min at 72 °C. PCR products were purified using Exonuclease I 
(Thermo Scientific, USA) and FastAP thermosensitive alkaline phosphatase 
(Thermo Scientific, USA) according to the manufacturer’s instructions. The 
sequencing for MLST was performed by a commercial laboratory (Macrogen Inc., 
Netherlands) with an ABI 3730 XL automated sequencer. The sequences were 
analyzed using the CLC Main Workbench (version 6.9.1, CLC bio, Denmark) with 
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the CLC MLST module (version 1.4.7, CLC bio, Denmark) comparing sequences 
of the housekeeping genes to the S. pseudintermedius MLST database 
(http://pubmlst.org/spseudintermedius/). For many isolates, the amplification 
of the tuf gene was weak when using primers tuf forward and tuf reverse, as 
described by Bannoehr et al. (2007). To try to improve the results, these primers 
were elongated by three bp at the 5’ end by choosing corresponding nucleotides 
as found in the complete genome sequence of Staphylococcus pseudintermedius 
HKU10-03 (NCBI GenBank accession no. CP002439) (Tse et al., 2011). The newly 
designed primers were tuf19F (5’-GTCCAATGCCACAAACTCG-3’) and tuf19R (5’-
CCAGCTTCAGCGTAGTCTA-3’). These were used both in the PCR amplification 
step and as sequencing primers. All used primers are presented in Table 4. 
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Table 4 Primers used for mecA, SCCmec, and MLST analyses of MRSP isolates identified at 
the Clinical Microbiology Laboratory of the Faculty of Veterinary Medicine, University 
of Helsinki, in 2010–2014. 
Target 
gene 
Primer Product 
size (bp) 
Sequence (5’-3’) Reference 
mecA detection 
mecA mecA P4 162 TCCAGATTACAACTTCACCAGG (Stegger et al., 2012) 
mecA mecA P7 - CCACTTCATATCTTGTAACG “ 
SCCmec typing (ccr gene complex) 
mecA mA1 286 TGCTATCCACCCTCAAACAGG (Kondo et al., 2007) 
mecA mA2 - AACGTTGTAACCACCCCAAGA “ 
ccrA1 α1 695 AACCTATATCATCAATCAGTACGT “ 
ccrA2 α2 937 TAAAGGCATCAATGCACAAACACT “ 
ccrA3 α3 1,791 AGCTCAAAAGCAAGCAATAGAAT “ 
ccrB1-B3 βc - ATTGCCTTGATAATAGCCITCT “ 
ccrA4 α4.2 1,287 GTATCAATGCACCAGAACTT “ 
ccrB4 β4.2 - TTGCGACTCTCTTGGCGTTT “ 
ccrC γR 518 CCTTTATAGACTGGATTATTCAAAATAT “ 
ccrC γF - CGTCTATTACAAGATGTTAAGGATAAT “ 
SCCmec typing (mec gene complex) 
mecI mI6 1,963 CATAACTTCCCATTCTGCAGATG (Kondo et al., 2007) 
IS1272 IS7 2,827 ATGCTTAATGATAGCATCCGAATG “ 
IS431 IS2(iS-2) 804 TGAGGTTATTCAGATATTTCGATGT “ 
mecA mA7 - ATATACCAAACCCGACAACTACA “ 
Multi-locus sequence typing 
tuf tuf F 500 GTCCAATGCCACAAACTCG (Bannoehr et al., 2007)* 
 tuf R - CCAGCTTCAGCGTAGTCTA “ 
cpn60 cpn60 F 552 GCGACTGTACTTGCACAAGCA (Bannoehr et al., 2007) 
 cpn60 R - AACTGCAACCGCTGTAAATG “ 
pta pta F 570 GTGCGTATCGTATTACCAGAAGG “ 
 pta R - GCAGAACCTTTTGTTGAGAAGC “ 
purA purA F 490 GATTACTTCCAAGGTATGTTT (Solyman et al., 2013) 
 purA R - TCGATAGAGTTAATAGATAAGTC “ 
fdh fdh F 408 TGCGATAACAGGATGTGCTT “ 
 fdh R - CTTCTCATGATTCACCGGC “ 
ack ack F 680 CACCACTTCACAACCCAGCAAACT “ 
 ack R - AACCTTCTAATACACGCGCACGCA “ 
sar sar F 521 GGATTTAGTCCAGTTCAAAATTT “ 
 sar R - GAACCATTCGCCCCATGAA “ 
bp, base pair; *, Modified for studies II and III by adding the underlined nucleotides, see text; -, 
complementary primer. 
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4.8.5 Pulsed-field gel electrophoresis (I–III) 
A modified version of the HARMONY protocol, as described by Murchan et al. 
(2003), was used for pulsed-field typing of MRSP isolates. Approximately 4×108 
colony forming units per strain plug were suspended in EC buffer (1 M sodium 
chloride, 0.5% polyoxyethylene 20 cetyl ether, 0.2% w/v sodium deoxycholate, 
0.5% w/v N-lauroyl-sarcosine sodium salt, 0.1 M EDTA, 6 mM 1.0 M Tris-HCl). 
The plugs were made by mixing the bacteria and EC buffer suspension with 20 µl 
of lysostaphin (1 mg/ml, Sigma-Aldrich, USA), and 200 µl of 2% SeaPlaque GTG 
agarose (Lonza Inc., USA). The digestion was performed using 10% NEBuffer 4 
or CutSmart buffer and 1.5 U SmaI per isolate (New England BioLabs Inc., USA) 
for 4–18 hours. Isolates that were not typeable using SmaI were macrorestricted 
using 1.5 U of AscI restriction enzyme per isolate (New England BioLabs Inc., 
USA). The pulsed-field electrophoresis was carried out in 1% SeaKem agar (Lonza 
Inc., USA) on the CHEF-DR III system (Bio-Rad Laboratories, USA). The total 
run time was 22 h; the first-block switch time was 0.1–15 s for 15 h, and the 
second-block switch time was 15–60 s for 7 h. The voltage for the run was 6 V/cm, 
with an included angle of 120°. 
Gels were stained with SYBR Safe DNA gel stain (Life technologies, USA) and 
analyzed using GelCompar II v. 6.6 software (Applied Maths NV, Belgium). 
Cluster analysis was performed by UPGMA (Unweighted Pair Group Method with 
Arithmetic Mean), based on the Dice similarity coefficient, with optimization and 
position tolerance both set at 1% for studies I and II. In study III, optimization 
and position tolerance were both set at 1.3%. Isolates were clustered using an 85% 
similarity cut-off for studies I and II, and using an 80% cut-off for study III. 
4.9 Ethical aspects 
Taking screening specimens for MRSP can cause very mild discomfort in the 
animal. Taking specimens from infection sites is medically necessary. In article I, 
the information was gathered as part of the infection control strategy of the VTH 
and was conducted to ensure patient safety in accordance with the hospital’s 
ethical guidelines. The owners of the animals were informed about the outbreak 
and study. They agreed to the investigation and the taking of necessary 
specimens, as well as any attempts to control the outbreak. 
In study II, the Guide Dog School of the Finnish Federation of the Visually 
Impaired gave full consent and actively participated in providing specimens and 
data. The Viikki Campus Research Ethics Committee has stated (statement 
4/2014) that the storage and use of excess animal patient specimens is ethically 
acceptable, which is also applicable to a study utilizing laboratory data and 
bacterial isolates, as was done in study III. All patient information in each study 
was handled confidentially and encrypted by assigning numbers to patients.
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5 Results and Discussion 
5.1 Hospital outbreak investigation (I) 
The MRSP outbreak spanned over a period of 14 months, during which 63 
patients were found to be infected (n = 27) or colonized (n = 36). The different 
types of infections caused by MRSP during the outbreak are summarized in Table 
5. Fifty-eight of the cases (92%) were dogs and five (8%) were cats. Breed variation 
was vast among dogs (over 40 different breeds), and all five cats were domestic 
short-haired cats.   
 
 
Table 5 Nosocomial infections (n = 27) caused by the MRSP outbreak strain (ST71, SCCmec 
II-III) in the Veterinary Teaching Hospital of Helsinki University in 2010 – 2011 (Study 
I). 
a, some cases required the removal of surgical devices and revision; b , patient had orthopedic surgery 
and several visits to the hospital, and otitis was subsequently diagnosed; c, Both patients presented 
with severe bite wounds; after a prolonged hospital stay MRSP was cultured from the wound; d, The 
patient presented with pneumonia, autoimmune myositis, and dermal vasculitis, and later developed 
an MRSP infection on the skin lesion; e, Colonization with MRSP preceded the cystitis. 
 
 
The index patient was a 3-year-old dachshund that was referred to the VTH 
emergency care unit at the end of October 2010. The critically ill dog suffered 
from systemic inflammatory response syndrome and disseminated intravascular 
coagulation due to necrotizing mastitis. These may have been postoperative 
complications after a cesarean section and an ovariohysterectomy performed at 
two different private veterinary clinics. Surgery was performed at the VTH to 
remove necrotized tissue. The dog was transferred to the intensive care unit 
Infection type Number of infections 
Surgical site infections (total) 19 
     Required surgical revision 3 
     Involved orthopedic devicesa 7 
     Others (uncomplicated) 9 
Other wound infections 3 
Otitisb 1 
Bite woundc 2 
Dermatitisd 1 
Cystitis complicated by urolithse 1 
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(ICU), where it was treated for 1 week. A bacteriological culture from the initial 
infection revealed a pure growth of Escherichia coli. Only two days after 
discharge, a surgical site infection was noted. The bacteriological culture revealed 
multidrug-resistant MRSP. An outbreak investigation was initiated due to this 
uncommon finding. This included culturing all infection sites and screening of 
patients potentially exposed to MRSP. 
The overall attack rate of MRSP was 2.1% (63/2969) among hospitalized 
patients and 3.8% (43/1121) among patients discharged from the ICU. MRSP was 
the cause of a surgical wound infection in 0.9% of surgical procedures (17/1864). 
The epidemic curve indicating the number of new cases per week is presented in 
Figure 3. During the MRSP outbreak at the VTH, the monthly incidence varied 
between zero and ten per a thousand patients. Peaks in incidence can be seen 
November 2010 and October 2011 (Figure 4). 
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Figure 4 The monthly cumulative incidence of all MRSPs and MRSPs displaying the outbreak 
antibiogram (MRSP ST71) among patients of the Veterinary Teaching Hospital of 
Helsinki University from January 2010 to December 2012. The outbreak period lasted 
from November 2010 to January 2012. In late 2011 a small cluster of ST45 among 
hospitalized patients contributed to an increase in incidence. From January 2012 
onwards, the great majority of new MRSP findings have been detected in screening 
targeted at risk patients on admission. In December 2012, the increase was not due 
to a cluster, but was due to the detection of different types of MRSPs, mainly in 
patients belonging to risk groups (Study I). 
 
Trace-back analysis to one case in June 2010 (Figure 4) did not reveal any apparent 
relationship with the outbreak. Screening of hospitalized patients and active case 
findings revealed many new cases (Figure 3, Figure 4). Initial control measures in 
late 2010 to early 2011 reduced the incidence, but new cases were detected in the 
summer and fall of 2011. These led to the implementation of extensive control 
measures. This seemed to disrupt and eventually end the outbreak. The 
investigation was interfered by a small cluster of MRSP ST45 detected in late 2011 
(Figure 4). The outbreak was declared over in January 2012, when no new MRSP-
positive patients were discovered in three consecutive screenings of hospitalized 
patients. 
A risk-based classification system was established during the outbreak 
described in study I. This system is still in use at the VTH and has proven effective 
in stopping further outbreaks of MRSP or other resistant bacteria. The system is 
presented in Table 6. 
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Table 6 The current risk based classification of patients at the Veterinary Teaching Hospital 
of Helsinki University and resulting measures. 
Classification Criteria (any of the following) Example of measures 
High-risk 
patients 
- MRSP-positive 
- Has been hospitalized >24 hours or has 
signs of a hospital acquired infection. 
- Treated in cohort ward 
- Barrier nursing 
- Surgery at the end of the day 
- Disinfection of facilities 
- Infection sites cultured 
- Standard precautions* 
 
Medium-risk 
patients 
- Has a history of recurrent ear or skin 
infection 
- Has a history of prolonged or numerous 
hospital visits or visits at other veterinary 
clinics 
- Has a history of prolonged or numerous 
antimicrobial treatments 
- Has been exposed to a patient with MRSP 
- Has had surgery elsewhere and has a 
surgical site infection 
- Has a suppurative wound infection 
 
- Screened for MRSP 
- Treated in separate rooms 
reserved for medium-risk 
patients 
- Surgery at the end of the day 
- Standard precautions 
- Infection sites cultured 
Low-risk 
patients 
- All other patients 
 
- All other rooms 
- Standard precautions 
*, Includes hand disinfection, a hygienic work routine, and the use of protective clothing in case of 
dirty procedures. 
 
Nine new MRSP findings with the outbreak antibiogram were detected during the 
follow up period (February 2012 to December 2012). Seven of these had been 
hospitalized during the outbreak and were identified upon admission. The other 
two were not spatially or temporally connected to the outbreak. The total toll of 
cases connected to the outbreak was therefore 70. No new cases were detected 
among hospitalized patients, despite frequent screenings. 
PFGE analysis supported the outbreak being due to the clonal spread of MRSP. 
Isolates clustered into one dominant pulsotype, A1 (n = 31), and four subtypes: 
A2 (n = 8), A3 (n = 6), and A4 (n = 1) with a one-band difference and A5 (n = 1) 
with a four-band difference (Figure 5). On the basis of the typing results for the 
three isolates, the strain responsible for the outbreak belonged to ST71 and 
harbored SCCmec II-III. 
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Figure 5 Dendrogram of 47 MRSP isolates with the outbreak antibiogram (see text). 
Staphylococcus pseudintermedius ATCC® 49444™ is displayed as a control. 
*Further characterized by multi-locus sequence typing and SCCmec typing. 
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The outbreak strain (ST71-SCCmec II-III) caused a number of nosocomial 
infections in patients of the VTH, ranging from dermatitis to osteomyelitis. Most 
infections were surgical-site infections after non-elective procedures. In one case, 
colonization was followed by a urinary tract infection, complicated by urolith 
formation, which led to surgery. In another case, an MRSP infection was the most 
likely cause for euthanasia, but this could not be confirmed, since no autopsy was 
performed. Infections caused by the outbreak strain led to prolonged hospital 
treatment or additional surgical procedures being required to combat the 
infection. The majority of infections were treated without systemic 
antimicrobials, although amikacin was used if necessary. In one case, a urinary 
tract infection was treated with nitrofurantoin. The fact that MRSP infections 
were manageable without systemic antimicrobials is encouraging, and this 
approach could even be considered in infections caused by susceptible bacteria, 
provided that no systemic signs are present. 
No common source for MRSP was identified during the outbreak. Several 
factors, however, suggest that this was a nosocomial outbreak, i.e. caused by HA-
MRSP. An outbreak requires the cases to be spatially and temporally connected, 
which they were. Also, the patients displayed no evidence of MRSP on admission, 
and molecular characterization supported clonal spread. Furthermore, the 
epidemic curve (Figure 3) suggests nosocomial patient-to-patient transmission, 
and all infections were related to hospital care, as they were surgical-site 
infections or other infections that appeared after prolonged hospital treatment. It 
is also very unlikely that MRSPs of colonized patients were community acquired, 
since this MRSP type was very rare prior to the outbreak and no similar type of 
MRSP was observed among outpatients or specimens submitted from private 
clinics during the outbreak. In addition, many of our cases (n = 30) had given a 
negative MRSP result in former bacteriological specimens taken on or soon after 
first admission. Furthermore, as suggested by Kasai et al. (2016), there is 
evidence to support the idea that ST71 isolates, carrying SCCmec II-III, could be 
characterized as HA-MRSP due to its properties. A similar SCCmec-based 
classification has previously been suggested in human medicine with regard to 
MRSA (Klevens et al., 2007). 
It is widely accepted that contaminated hands favor the spread of nosocomial 
pathogens (Weese, 2012). This may be efficiently controlled in hospitals by 
increasing the use of alcoholic hand rubs, as has been proven with MRSA (Lederer 
et al., 2009; Sakamoto et al., 2010). Furthermore, barrier nursing, as was 
implemented during our outbreak, has additionally been effective in reducing 
HA-MRSA (Perlin et al., 2013). Fomites may also play a role in the spread of 
hospital-associated pathogens, emphasizing the necessity of a clean environment 
and clothing (Boyce, 2007; Singh et al., 2013; Wilson et al., 2011). The 
environment was, however, probably not a major contributing factor in our 
outbreak, as only 1 out of 65 environmental specimens was positive for MRSP. It 
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is possible and even likely that the rapid response to the outbreak, along with the 
intensification of routine environmental cleaning procedures, reduced 
environmental contamination and effectively prevented environmental spread. In 
addition, cohorting, patient flow planning, emphasis on hand hygiene, barrier 
nursing, and prudent antimicrobial use were probably important (Weese, 2012).  
Severe measures were required before control of the outbreak was gained. 
Reasons for the long duration of the outbreak are likely to be numerous. Studies 
have shown that MRSP ST71 is capable of efficient dissemination (Perreten et al., 
2010) and biofilm formation (Osland et al., 2012). The initial lack of resources 
allocated for infection control probably contributed to the increased number of 
cases. In addition, new employees not familiar with the hygiene practices during 
the summer of 2011, combined with the lack of personnel due to holidays, may 
have contributed to the increase in incidence. On the other hand, more effective 
tracking of exposed patients and the appointment of a hygiene nurse seemed to 
reduce the number of new cases. Moreover, the cleaning and disinfection at the 
end of 2011 probably favored the cessation of the outbreak. 
The role of colonized patients is likely to be underestimated in veterinary 
hospitals. While standard hygiene practices are effective in reducing the spread 
of MDR pathogens, extra precautions taken when treating identified carriers 
probably nullifies the risk of spread. Little evidence is available to support the use 
of a search-and-destroy policy, or decolonization treatment specifically for MRSP, 
as has been done with MRSA in some countries (Holzknecht et al., 2010; van Trijp 
et al., 2007). However, our search-and-isolate policy bears similar features. Since 
the outbreak, only sporadic cases of MRSP displaying the outbreak antibiogram 
have been identified, mainly among acknowledged risk patients, which indicates 
the success of the present policy. The total number of newly identified MRSP 
cases at the VTH has also significantly decreased since the outbreak. 
5.2 Estimates for MRSP occurrence 
The estimates of the occurrence of MRSP are based on the prevalence study on 
guide dogs, as well as crude estimations of prevalence by calculating the 
proportion of small animal clinical and screening specimens that revealed MRSP. 
5.2.1 Prevalence of MRSP among guide dogs (II) 
Screening specimens were taken from 132 dogs, of which four were MRSP-
positive (prevalence estimate for the population 3%, 95% CI: 1–8%). No MRSA-
positive dogs were identified (prevalence estimate 0%, 95% CI: 0–3%). The breed 
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and sex of the sample population was representative of the target population, 
while the dog groups and age differed from that of the target population (Table 7). 
 
Table 7  Comparison of demographics in the sample and target populations of the Finnish 
Guide Dog School’s dogs in study II. 
  Sample population Target population Statistical 
difference 
  n = 132 %* n = 308 %* P-value (method) 
Sex      
 Male 65 49 158 51 0.92 
(Fisher’s exact test)  Female 67 51 150 49 
Breed      
 Labrador 
retriever 
124 94 287 93 0.84 
(Fisher’s exact test) 
 Other 8 6 21 7 
Dog group      
 Guide dog 56 42 187 61 0.01 
(Fisher’s exact test)  Dog in training 68 52 103 33 
 Breeding dog 8 6 18 6  
      
Age Mean 
(min – max) 
Median Mean 
(min – max) 
Median  
  3.8 
(0.2 – 13.9) 
2.1 4.6 
(0.2 – 13.9) 
3.9 0.03 
(t-test) 
*Percentage values are rounded. Statistically significant P-values (<0.05) are bolded. 
 
 
The observed prevalence of MRSP matched the predicted prevalence value. 
While no MRSA-positive dogs were discovered, it is important to note that with 
the CI used, the prevalence of MRSA may be as high as 3%. As seen in Table 7,  
dogs in training were overrepresented at the expense of guide dogs. This 
discrepancy is explainable by the ease of access, as dogs in training were more 
readily available for sampling at the GDS. This is also a reason for the difference 
in age, since dogs in training are younger than other dogs. The sample population 
represented the target population well in relation to breed and sex, and the 
targeted sample size (152) was close to the one obtained (132). The fact that the 
sample population was slightly skewed could, however, have impacted the results 
of the study. 
Published studies regarding the prevalence of MRSP or MRSA in Finnish dogs 
are not available. Furthermore, only a few studies exist that have measured the 
prevalence of MRSP among specific animal groups. In a study of shelter animals 
by Gingrich et al. (2011) in Colorado, USA, the prevalence of MRSP in dogs was 
3%, while the prevalence of MRSA in dogs was 0.5%. These numbers coincide 
quite well with our study. In Slovenia, the prevalence of MRSP (then MRSI) was 
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1.5% (3/200) in clinically healthy dogs in a community, while MRSA was not 
discovered (Vengust et al., 2006). Regarding veterinary hospitals, (Hanselman et 
al., 2008) reported a MRSP prevalence of 2.1% and MRSA prevalence of 0.5% in 
dogs upon admission in Ontario, Canada. A similar study conducted in Hannover, 
Germany, reported a higher MRSP prevalence (7.4%) (Nienhoff et al., 2011b). 
Furthermore, Boost et al. (2008) investigated the prevalence of S. aureus in dogs 
and their owners in Hong Kong. They found an MRSA prevalence of 0.7% among 
the dogs investigated, which falls into the 0–3% prevalence estimate in our study 
and corresponds well to our laboratory data. Further study is, however, needed to 
ascertain the prevalence of MRSP and MRSA in the average dog population, as 
well as subpopulations, to identify target groups for preventive measures. 
5.2.2 Incidence and occurrence of MRSP among clinical specimens 
The overall incidence (dogs and cats) of MRSP declined from 2011 to 2013 and 
remained stable from 2013 to 2015 (Figure 6). The same trend could also be seen 
for dogs and cats when considered separately. Out of all investigated canine 
clinical specimens (n = 9174), MRSP was isolated from 2.8% (2.5% if cats are 
included), a proportion similar to the MRSP prevalence in the Finnish guide dog 
population (3%). While this figure of 2.8% is not a true prevalence, it may be used 
as a crude approximation of the prevalence in an average canine population from 
which bacterial cultures have been taken, in order to design future prevalence 
studies. In feline specimens, the same figure was 0.4% (n = 1639).  
 
Figure 6 Yearly incidence of MRSP among clinical specimens from dogs (■), cats (▲) and 
overall (●) per thousand specimens at the Clinical Microbiology Laboratory of the 
Faculty of Veterinary Medicine, University of Helsinki. Numbers next to data points 
indicate the total number of specimens for each animal species that year. 
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5.2.3 Occurrence of MRSP among risk patients (III) 
MRSP from screening specimens from patients with identifiable risk factors, such 
as those listed in Table 6 (e.g. previous history of antimicrobial therapy or skin 
disease), was quite common, with an overall prevalence of over 9%.  Screening 
specimen data for dogs and cats by year, are presented in Table 8. 
 
Table 8 The proportion of MRSP per year among screening specimens from dogs and cats in 
Finland in 2011–2015. 
 Dogs Cats 
Year MRSP% n MRSP% n 
2011 June* 9.2 347 11.5 52 
2012 8.4 452 0.0 59 
2013 6.2 436 0.0 28 
2014 10.2 551 0.0 24 
2015 11.5 451 0.0 34 
Total 9.2 2237 3.0 197 
*, the MRSP outbreak at the VTH was still ongoing in 2011; MRSP, methicillin-resistant S. 
pseudintermedius; n, number of specimens. 
 
Prevalence data for risk patients are difficult to compare with existing studies, as 
no similar study has to our knowledge been conducted. As discussed above, the 
prevalence of MRSP varies quite substantially between studies and study 
populations. Our data are based on patients with identifiable risk factors for 
MRSP that have visited a veterinarian, either at the VTH or a private veterinary 
clinic in Finland. Thus, it would be inappropriate to compare the number to a 
population of healthy animals, such as those studied by Kjellman et al. (2015), or 
Gingrich et al. (2011). However, a study comparing the prevalence of S. 
(pseud)intermedius and MRSP, as well as other coagulase-positive staphylococci, 
in dogs with healthy and inflamed skin showed a similar difference compared to 
the prevalence estimates of our studies (Griffeth et al., 2008). In the study, 2% of 
healthy dogs (n=50) carried MRSP, while 7% of dogs with inflamed skin (n=59) 
carried MRSP. 
 
5.3 Risk factors for MRSP (I–III) 
In study I, four risk factors were identified among patients at risk during the 
MRSP outbreak at the VTH: skin lesions, antimicrobial treatment, and the 
cumulative number of days in the intensive care unit or in the surgery ward. In 
study II, although only a few animals were MRPS-positive, antimicrobial therapy 
and veterinary visits were risk factors among the Finnish guide dog population. 
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In study III, risk factors for a clinical S. pseudintermedius isolate being MRSP 
were ongoing antimicrobial or beta-lactam treatment during sampling, and being 
male. Among patients screened for MRSP, being a dog and receiving multiple 
antimicrobials during sampling were statistically significant risk factors for 
MRSP. Moreover, among both clinical and screening specimens in study III, the 
specimen originating from a private clinic increased the odds of S. 
pseudintermedius being MRSP. Results of the statistical analyses from each study 
are presented in Table 9, Table 10, Table 11, and Table 12. Note that in the tables, n 
refers to the number of dogs with the factor in question, while % refers to the 
proportion out of the total number of dogs from which data were available. For 
instance in Table 11 antimicrobial treatment data were available from 209 dogs 
among MRSP cases (84/0.402).  
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Table 9 Risk factors associated with the acquisition of MRSP during the outbreak in the 
Veterinary Teaching Hospital of Helsinki University in 2010–2011 (Study I). 
OR, Odds ratio; CI, Confidence interval. Statistically significant P-values (<0.05) are bolded. 
 
  
    Univariable logistic 
regression 
Multivariable logistic 
regression 
Binary variables MRSP-pos 
(ntot = 55) 
 
MRSP-neg 
(ntot = 213) 
Unadjusted OR 
(95% CI) 
Wald 
P 
Adjusted OR 
(95% CI) 
Wald 
P 
  n % 
 
n %  
 
  
Demographics          
Gender: M vs. F 30 54.5  96 45.1 1.46 (0.80-2.66) 0.212   
Species: dog  vs. cat 50 90.9  192 90.1 1.09 (0.39-3.06) 0.864   
Epidemiological data          
Skin lesion 49 89.1 
 
85 39.9 12.40 (5.06-30.37) < 0.001 6.24 (2.30-
16.97) 
0.0003 
Antimicrobial treatment 52 94.6  130 61.0 11.07 (3.33-36.79) < 0.001 3.80 (1.04-
13.92) 
0.0442 
Surgical procedure 45 81.8 
 
67 31.5 9.81 (4.65-20.70) < 0.001   
Cephalosporin treatment 21 38.2  24 11.3 5.10 (2.54-10.26) < 0.001   
Enrofloxacin treatment 18 32.7  33 15.5 2.70 (1,3-5.2) 0.005   
Severity (1 vs. others) 46 85.5  8 14.5 2.84 (1.3-6.4) 0.012   
Aminopenicillin treatment 34 61.8  93 43.7 2.09 (1.14-3.85) 0.018   
Treatment in ICU 41 74.6  126 59.2 2.02 (1.03-3.95) 0.039   
Proton pump inhibitor 
treatment 
36 65.5  114 53.5 1.65 (0.89-3.06) 0.115   
Orthopedic vs. soft tissue 
surgery 
20 44.4  20 30.3 1.84 (0.83-4.08) 0.132   
Other antimicrobial 
treatment 
12 21.8  32 15.0 1.58 (0.75-3.33) 0.229   
Emergency surgery 6 13.6  9 13.4 1.02 (0.33-3.13) 0.976   
Continuous variables MRSP-pos 
(ntot = 55) 
 MRSP-neg 
(ntot = 213) 
Unadjusted OR 
(95% CI) 
Univari
ate P 
Adjusted OR 
(95% CI) 
Multiple 
regression P 
 n mean  n mean     
Demographics          
Bodyweight 55 20.7  201 19.2 1.01 (0.99-1.03) 0.493   
Age 55 4.8  212 4.9 1.01 (0.92-1.10) 0.791   
Epidemiological data          
Cum. days in ICU 55 2.9  213 1.5 1.39 (1.20-1.61) <0.001 1.3 (1.1-1.6) 0.0007 
Cum. days in surgery 
ward 
55 3.4  213 1.1 1.28 (1.15-1.42) <0.001 1.1 (1.0-1.3) 0.0401 
Cum. days in hospital (all 
wards) 
55 7.2  213 4.5 1.15 (1.08-1.24) <0.001   
Cum. days of proton 
pump inhibitors 
36 5.5  114 2.9 1.08 (1.01-1.17) 0.037   
Length of surgical 
procedure (10 min 
change) 
41 203.2  57 170.9 1.04 (0.99-1.10) 0.080   
Cum. days in other wards 55 2.0  213 2.6 0.92 (0.81-1.05) 0.210   
Cum. days antimic. given 55 12.0  213 5.4 1.01 (0.99-1.02) 0.364   
Cum. days of enroflox. 18 6.5  33 4.7 1.03 (0.96-1.11) 0.459   
Cum. days of aminopen. 34 13.9  93 10.1 1.00 (0.99-1.02) 0.481   
Cum. days cephalosp. 21 5.3  23 4.1 1.03 (0.93-1.15) 0.518   
Cum. days of other 
antimic. 
12 4.7  32 6.7 0.98 (0.91-1.06) 0.614   
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Table 10 Risk factors associated with MRSP in the Finnish Guide Dog School population in 
2014 (Study II). 
OR, Odds ratio; CI, Confidence interval using Firth’s bias adjustment (see text); *, for the past 12 
months. Statistically significant P-values (<0.05) are bolded.  
    Univariable logistic regression 
Categorical variables MRSP-pos 
(n = 4) 
 
MRSP-neg 
(n = 128) 
Unadjusted OR 
(95% CI) 
Likelihood 
P 
  n % 
 
n %  
 
Demographics        
Gender: F vs.M 3 75.0  62 48.4 2.48 ( 0.40-26.13) 0.338 
Breed (Labrador retriever vs. 
other) 
4 100.0  120 93.8 0.64 (0.06-86.75) 0.779 
Dog bought vs. bred by school 0 0.0  13 10.2 0.95 (0.01-9.70) 0.973 
Dog group        
  Breeding vs. training 2 50.0  6 4.7 8.39 (1.12-64.13) 0.012 
  Training vs. working 0 0.0  68 53.1 0.16 (0.00-2.01)  
Epidemiological data        
History of ear or skin disease 1 25.0  63 52.1 0.40 (0.04-2.48) 0.328 
Antimicrobial treatment* 3 75.0  66 52.8 2.09 (0.33-21.99) 0.441 
Continuous variables MRSP-pos 
(n = 4) 
 MRSP-neg 
(n = 128) 
Unadjusted OR 
(95% CI) 
Likelihood 
ratio P 
 n mean  n mean   
Demographics        
Age 4 5.8  128 3.8 1.18 (0.92-1.49) 0.185 
Epidemiological data        
Number of veterinary visits* 4 9.8  128 4.9 1.23 (1.030-1.48) 0.025 
Number of antimicrobial courses* 4 2.8  126 1.0 1.63 (1.04-2.55) 0.035 
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Table 11 Risk factors associated with the discovery of MRSP among canine clinical S. 
pseudintermedius isolates taken in 2012–2015 (Study III). 
OR, Odds ratio; CI, Confidence interval; *, antimicrobial group variables were analyzed separately for 
patients that had received antimicrobials. Statistically significant P-values (<0.05) are bolded. 
 
 
  
 
MRSP 
(ntot = 227) 
 
MSSP 
(ntot = 1501) 
Univariable logistic regression 
Multivariable logistic 
regression 
 n %  n % 
Unadjusted OR 
(95% CI) 
Univariate 
P 
Adjusted OR 
(95% CI) 
Wald 
P 
Private clinic vs. 
Univ. Teach. Hosp. 
192 84.6  1140 75.9 1.74 
(1.19-2.54) 
0.004 1.88 
(1.25-2.81) 
0.003 
Gender: male vs. 
female 
150 67.6  761 52.3 1.90 
(1.41-2.56) 
<0.001 1.83 
(1.34-2.51) 
<0.001 
Deep lesion 
specimen 
31 13.7  234 15.6 0.86 
(0.57-1.28) 
0.452   
Superficial lesion 
specimen 
173 76.2  1147 76.4 0.99 
(0.71-1.37) 
0.946   
Urine specimen 
8 3.5  81 5.4 0.64 
(0.31-1.34) 
0.238   
Other specimens 
15 6.6  39 2.6 2.65 
(1.43-4.90) 
0.002 1.65 
(0.77-3.51) 
0.196 
Antimicrobial 
treatment during 
sampling 
84 40.2  264 19.1 2.84 
(2.09-3.87) 
<0.001 2.67 
(2.09-3.93) 
<0.001 
Antimicrobial groups: * 
Systemic beta-
lactams 
60 71.4  150 57.3 1.87 
(1.10-3.18) 
0.022 1.87 
(1.10-3.18) 
0.022 
Multiple systemic 
antimicrobials 
1 1.2  6 2.3 0.51 
(0.06-4.33) 
0.541   
Other systemic 
antimicrobials 
15 17.9  63 23.9 0.25 
(0.37-1.30) 
0.252   
Topical 
antimicrobials 
8 9.5  40 15.3 0.58 
(0.26-1.30) 
0.189 0.90 
(0.35-2.29) 
0.825 
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Table 12 Risk factors associated with the discovery of MRSP among canine screening 
specimens taken during 2012–2015 (Study III). 
OR, Odds ratio; CI, Confidence interval; *, antimicrobial treatment in general was not significant in the 
univariable analysis, and antimicrobial groups were therefore included in the model. Statistically 
significant P-values (<0.05) are bolded. 
 
 
Antimicrobial therapy, either previous or during sampling, was implicated in 
some way as a risk factor in all studies. In addition, in studies I and II, a prolonged 
hospital stay and veterinary visits increased the risk of being MRSP (such data 
were not available for study III). The results from study I should not, however, be 
generalized to the overall population, as the study population consisted of 
patients hospitalized that were at risk of acquiring MRSP during an outbreak. 
Likewise, risk factor results from the studies are only valid for the population 
described, although the target population of study III was quite large, comprising 
small animals with infections from which a bacteriological specimen is obtained. 
It is interesting, although perhaps unsurprising, that the risk factors remained 
fairly similar between the studies. While several studies have evaluated the risk 
factors for MRSP infection, one risk factor has been documented above all: 
antimicrobial therapy (Eckholm et al., 2013; Huerta et al., 2011; Kasai et al., 2016; 
Nienhoff et al., 2011b). Specific antimicrobial drugs, such as clindamycin have 
also been indicated as increasing the risk of acquiring MRPS (Beck et al., 2012). 
Likewise, Kasai et al. (2016) found that treatment with beta-lactams was a risk 
factor for MRSP being recognized among clinical S. pseudintermedius isolates, 
similarly to the results of study III. Our results, as well as the results from the 
studies cited, are hardly surprising, as MRSP, commonly being MDR, is given a 
clear competitive advantage in hosts where the normal microbiota is suppressed 
by antimicrobial therapy. 
 
MRSP-pos 
(ntot = 173) 
 
MRSP-neg 
(ntot = 1717) 
Univariable logistic regression 
Multivariable logistic 
regression 
 n %  n % 
Unadjusted OR 
(95% CI) 
Univariate 
P 
Adjusted 
OR 
(95% CI) 
Wald 
P 
Private clinic vs. 
Univ. Teach. Hosp. 
67 38.7  521 30.3 1.45 
(1.05-2.00) 
0.024 1.54 
(1.09-2.18) 
0.015 
Gender: male vs. 
female 
92 54.4  849 50.2 1.19 
(0.86-1.63) 
0.295   
Antimicrobial 
treatment during 
sampling* 
45 29.4  446 28.5 1.04 
(0.73-1.50) 
0.815   
Systemic beta-
lactams 
20 13.1  219 14.0 0.92 
(0.57-1.51) 
0.751   
Multiple systemic 
antimicrobials 
10 6.5  56 3.6 1.88 
(0.94-3.77) 
0.074 2.14 
(1.06-4.32) 
0.034 
Other systemic 
antimicrobials 
7 4.0  108 6.3 0.63 
(0.29-1.37) 
0.243   
Topical 
antimicrobials 
6 3.9  45 2.9 1.38 
(0.58-3.28) 
0.470   
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Furthermore, while hospitalized patients were at risk of acquiring MRSP 
during the hospital outbreak, it was curious to find that even among the small 
positive group in study II, frequent veterinary visits was a risk factor. Similar 
results have been reported by other studies, where previous hospitalization or 
frequent veterinary visits have been implicated (Eckholm et al., 2013; Lehner et 
al., 2014; Nienhoff et al., 2011b). 
In study I, skin lesions were also associated with a higher risk of MRSP. While 
this variable did not differentiate whether the skin lesion was due to dermatitis, 
surgery, or something else, there is evidence to suggest that a chronic 
dermatological disorder is a risk factor for MRPS (Huerta et al., 2011). This is, 
however, probably due to long-term antimicrobial exposure, frequent veterinary 
visits (Lehner et al., 2014), and properties of the diseased skin (Simou et al., 
2005), all of which could favor the acquisition of MRSP. There is also evidence to 
suggest that animals that carry MRSP are at a higher risk of getting an SSI, caused 
by any bacterium, post-surgery (Nazarali et al., 2015). 
It was a surprising finding that S. pseudintermedius isolates being MRSP was 
more likely in specimens from private clinics compared to the VTH. This finding 
is given more credibility by the same result being obtained from the analysis of 
screening specimens. The reasons for this may be numerous. The VTH is not 
exclusively a referral hospital, but also treats first opinion patients. This probably 
dilutes some of the effect that chronically ill patients may be contributing to the 
prevalence of MRSP at the VTH. More importantly, the threshold to obtain 
bacteriological specimens early in the infection process is probably higher among 
private clinic veterinarians. The VTH has had a strict policy to obtain specimens 
in all cases of suspected bacterial infection since the MRSP outbreak in 2010–
2011. It is also likely that screening criteria for risk patients are wider at the VTH 
compared to private clinics that, in our experience, mainly screen dermatological 
patients. This is a known risk group for MRSP, at least in part due to frequent 
antimicrobial therapy and veterinary visits (Lehner et al., 2014; Nienhoff et al., 
2011b; Soares Magalhaes et al., 2010). Dissimilarities in patient populations may 
thus explain a difference in the proportion of MRSP, as has previously been 
reported (Beever et al., 2015). 
Other risk factors identified in study III included gender, which is a risk factor 
that no study, to our knowledge, yet has reported. The reason for this is unclear. 
Studies have not found sex to be a predisposing factor for atopic dermatitis or 
food allergy (Bizikova et al., 2015; Nodtvedt et al., 2007; Verlinden et al., 2006). 
It is possible, or even likely, that some unknown variable could explain the result. 
Regardless, a German study investigating risk factors for MRSA in humans at a 
University hospital determined that male gender was a significant risk factor for 
MRSA acquisition. According to the authors, this may have been due to other 
factors that are associated with both the male gender and MRSA acquisition 
(confounding factors). These included diabetes mellitus-related terminal renal 
 69 
failure, requiring dialysis, as well as invasive devices, such as bladder catheters. 
Our result may also be only due to chance, as gender was not observed to be a risk 
factor for MRSP in screening specimens. 
It is also important to note that none of the studies was a longitudinal cohort 
study. Our results only show correlation, not causation, although causation may 
have been previously proven by other studies for some variables, such as 
antimicrobial treatment. 
5.4 The role of cats 
Five out of 55 cases (9%) in the VTH outbreak were cats. Cats were not separately 
analyzed in study I due to their low number and because it was deemed irrelevant, 
as the study population comprised patients of the VTH, not either species 
specifically. For study III, cats were omitted from the analyses due to their low 
number, as explained in section 4.7.3. Clinical specimens from dogs did, however, 
reveal more S. pseudintermedius and MRSP than those from cats. Furthermore, 
after 2011, not a single MRSP was isolated from feline screening specimens (n = 
145), and only three were discovered in feline clinical specimens (n = 1509). It is 
therefore reasonable to conclude that the number of infected cats during the 
outbreak was disproportionately large due to the infection pressure at the hospital 
at that time. The post-outbreak results are unsurprising, as both S. 
pseudintermedius and MRSP colonization are less common in cats (Hanselman 
et al., 2009; Ruscher et al., 2009). Screening of cats for MRSP carriage, even if 
they have risk factors, is thus deemed unnecessary. Screening feline patients 
during MRSP outbreaks may, however, be important. It is worth noting that one 
study has indicated that cats (compared to dogs) have a higher risk of a clinical S. 
pseudintermedius isolate being MRSP (Lehner et al., 2014). The number of 
isolates from cats in the study was, however, low. 
5.5 Molecular epidemiology of MRSP 
5.5.1 Molecular epidemiology (I–III) 
The outbreak in study I was caused by the well-established global MDR MRSP 
clone ST71-SCCmec II-III (Perreten et al., 2010). This was the most prevalent 
clone among MRSP isolates during 2010–2011 in Finland, although a shift in 
clonality has since occurred (see below). A parallel, smaller cluster of ST45 
isolates was also detected in the later stage of the outbreak. 
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Characteristics of the four MRSP isolates of study II are compared in Figure 7: 
four were from the prevalence study (P-833, P-834, P-843, and P-860), two (P-
853, and 2014-887) were from contact dogs of guide dog P-833 and three were 
isolates that had been preserved in 2012-2013 from other guide dogs (P-495, P-
527 and P-781). All isolate except one (P-781) were multidrug resistant (MDR, 
resistant to ≥3 antimicrobial groups). The MRSP isolate of a contact dog, 2014-
887, shared an identical antibiogram with the MRSP of guide dog P-833, but the 
other contact’s isolate (P-853) differed from these (Figure 7). 
 
 
Figure 7 SmaI dendogram and antibiograms of the MRSP isolates investigated in the Finnish 
Guide Dog School MRSP study. 
Dogs P-833, P-834, P-843, and P-860 were in the prevalence study, other dogs were contacts. Dogs 
P-833, P-853, and 2014-887 lived in the same household. OX, oxacillin; E, erythromycin; DA, 
clindamycin; SXT, sulphamethoxazole/trimethoprim; TE, tetracycline; FD, fucidic acid; ENR, 
enrofloxacin; CN, gentamicin; AK, amikacin; R, resistant; S, susceptible; NT, non-typeable; NA, not 
analyzed; Unk, the result from the SCCmec analysis of isolate P-781 was inconclusive (see text). The 
gray dashed line indicates the 85% cut-off value. 
 
 
All isolates except for 2014-887, were available for molecular typing. Of the four 
isolates from the prevalence study, three (P-833, P-843, and P-860) were non-
typeable by SmaI restriction, but gave identical AscI restriction profiles 
(Appendix 1). Both SmaI and AscI restriction patterns indicated that the other 
five isolates were not closely related. The four MRSP isolates from the prevalence 
study represented three different sequence types (Figure 7). Two were of ST45, 
while ST71 and ST402 had one representative each. The ST402 strain was a single 
locus variant (SLV) of ST45. The isolate from dog P-495 was an SLV of ST150. 
Isolates belonging to ST71 harbored SCCmec II-III. The ST45 and ST402 isolates 
were non-typeable by the SCCmec method used, as only the mecA gene was 
amplified in M-PCR-1. Isolate P-781, which belonged to ST403, gave an unusual 
result in the SCCmec analysis, as it seemed that products specific to the gene 
alleles ccrA2 and ccrA4 were amplified in M-PCR-1 (Appendix 2). 
Out of the 362 MRSP isolates in study III (197 from clinical specimens, 165 
from screening specimens), 279 were typeable using SmaI macrorestriction. 
These clustered into 19 (A to S) different clusters with four or more isolates 
(Appendix 3). Eighty-three isolates could only be typed by AscI macrorestriction, 
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and formed two clusters (T and U) and one singleton in PFGE analysis (Appendix 
4). In total, 87 isolates from 71 different PFGE clusters or singletons (SmaI or 
AscI) were investigated by MLST and SCCmec. Forty-two different STs were 
identified, including 19 new STs: 621 and 625–642 
(https://pubmlst.org/spseudintermedius/). All SmaI non-typeable isolates 
belonged to CC45. 
The proportion of isolates from each CC or ST changed from year to year, 
indicating increasing diversity in the MRSP population (Figure 8). All identified 
STs and their clonal and genetic relatedness are presented in Figure 9 A and B. Six 
STs grouped together with previously described CCs (CC45 and 258) (Duim et al., 
2016). STs in the CC258 group were scattered in the sequence comparison tree, 
while STs in the CC45 group were more alike. 
 
           30                     87        87    55              103 
 
Figure 8 Proportion of clonal complexes or sequence types of methicillin-resistant 
Staphylococcus pseudintermedius by year in 2010–2014. The data are based on the 
extrapolation of MLST analysis results to the corresponding PFGE cluster. Numbers 
on top of the columns indicate the number of isolates. Other, miscellaneous sequence 
types. 
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Figure 9 (previous page) Genetic relationship of methicillin-resistant Staphylococcus 
pseudintermedius in Finland (2010 to 2014). A: goeBURST analysis conducted at the 
double-locus variant level, with triple-locus variants (connected with gray dashed 
lines) added to show further relatedness. Line numbers and shading indicate the 
number of differing loci between sequence types. CC, clonal complex. Gray areas 
highlight CCs. Gray boxes with black text, group founder; black boxes with white text, 
sub-group founder; white boxes with black text, common node; gray boxes with white 
text, triple-locus variant. B: A phylogenetic tree based on the alignment of all MLST 
genes of each ST. Only posterior probabilities >0.7 are shown. Gray shades indicate 
clonal complex groups as assigned by goeBURST analysis. *, clonal complex 
founder; †, single-locus variant; ‡, double-locus variant. 
 
Four different SCCmec types, covering 60 out of the 87 (69%) investigated 
isolates, were identified. Twenty-seven isolates (31%) were non-typeable, either 
due to a lack of a PCR product or because the result did not match SCCmec types 
I–VI (Appendix 5). The number of isolates found to carry each SCCmec, as well 
as the STs in which these were found, are presented in Table 13. 
 
Table 13 The number of MRSP isolates with each identified SCCmec, as well as the sequence 
types associated with them. 
SCCmec 
Number of 
isolates 
Sequence Type(s) 
II 1 498 
II-III 19 71 
IV 37 
258, 342, 413, 415, 475, 561, 592, 621, 
625, 626, 630, 631, 632, 633, 634, 635, 638, 
639, 640, 641 
V 3 183, 404, 642 
Non-typeable 27 
21, 41, 45, 84, 121, 150, 152, 263, 298, 
305, 402, 403, 561, 628, 636, 637 
 
 
The identification of 23 previously identified and 19 new STs is a testament to the 
diverse nature of the MRSP population in Finland. A changing trend was evident, 
as the population diversified during the time frame investigated (Figure 8). It is, 
however, important to note that in 2010–2011, many isolates originated from the 
VTH outbreak. Before the outbreak, MRSP was a very uncommon finding in the 
VTH, although previously published surveillance data indicate that MRSP arrived 
in force in Finland in 2009, when a sharp increase in the proportion of MRSP was 
observed (FINRES-Vet, 2015). A Swedish study (isolates from 2008 to mid-2010) 
revealed a fairly homogeneous MRSP population, with 96% (216/226) of the 
isolates representing the predominant European lineage, ST71 (Borjesson et al., 
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2012). This clone was also the most common ST in Finland in 2010–2011, but has 
diminished since (Figure 8). As in our data, a change in the MRSP population has 
also been observed in Sweden since 2010 (SWEDRES-SVARM, 2016). There, 20 
out of 58 MRSP isolates (34%) were ST258 in 2015. CC258 was the third most 
common CC in our study, and was the largest clone in Norway in a recent study 
(Kjellman et al., 2015). Additionally, CC258 has recently been reported as a major 
CC in both the Netherlands (Duim et al., 2016) and Denmark (Damborg et al., 
2016). These studies also reported a marked diversity in the MRSP population in 
recent years. It thus appears that ST71 has lost its sustainability and CC258 is only 
filling the gap as a more successful lineage. ST71 carries SCCmec II–III, which has 
only been found in related STs and ST354 (Damborg et al., 2016; Ishihara et al., 
2016). The immobility of this element may be an underlying reason for the demise 
of the clone. In contrast, our data indicate that SCCmec IV, in particular, is readily 
transferred between different clones, or is received from other staphylococci, as 
it was identified in 20 different STs. The acquisition of SCCmec elements by MSSP 
from MRSP, CoNS, or MRSA may explain the plethora of STs in MRSP. Our 
findings indicate that the epidemiology of MRSP is changing; clonal spread is 
becoming less significant and the spread of SCCmec elements is more common. 
This could make it more difficult to control the spread of MRSP. 
Contrary to CC71, CC45 has maintained a steady proportion, with an over 20% 
annual share of the MRSP isolates in 2011–2014. Representatives of this CC have 
been detected at least in Sweden (SWEDRES-SVARM, 2015), the Netherlands 
(Duim et al., 2016), and in Israel and Thailand (Kadlec et al., 2016; Perreten et 
al., 2013), but has been rather rare in reports from Europe (Duim et al., 2016; 
SWEDRES-SVARM, 2015). Representatives of ST45 are typically non-typeable by 
SmaI PFGE (Perreten et al., 2013), as was the case in our study. Interestingly, 
80% (66/83) of CC45 isolates showed the same basic antibiogram, only being 
susceptible to trimethoprim/sulfamethoxazole and fusidic acid (Appendix 4). The 
distribution of STs among clinical isolates and screening isolates was similar, with 
ST71 being the most common and ST45 being the second most common ST in 
both groups (data not shown). 
The sequence alignment and eBURST analyses grouped the identified STs 
quite differently. For example, STs 258 and 413, single-locus variants, were placed 
in different groups in the maximum likelihood tree (6 nucleotide differences in 
one locus), while ST638, a double-locus variant to ST258, was deemed nearly 
identical to ST258 (4 nucleotide differences in two loci) in the maximum 
likelihood tree (Figure 9). Performing eBURST analysis of MLST data has become 
common when analyzing the clonality of MRSP. However, it does appear to be a 
crude way of assigning genetic relatedness. A single locus, e.g. cpn60 alleles 1 and 
10, may have 26 single nucleotide differences. All other alleles being identical, two 
isolates would be considered single-locus variants, and be assigned the same CC. 
On the other hand, two isolates that are triple-locus variants, but only by one 
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nucleotide in each locus (e.g. ack 1 and 2, fdh 1 and 5, and sar 1 and 7), would not 
be assigned to the same CC, even though the total number of nucleotide 
differences is much smaller (3 versus 26). It could be beneficial to determine 
genetic relatedness based on the actual sequences, as was done by Kjellman et al. 
(2015), rather than by comparing combinations of allele numbers, as much 
resolution is lost in the latter method. It is, however, likely that whole genome 
sequencing will replace eBURST analysis once its costs decrease. 
The epidemiology of MRSP is complex, being a combination of clonal 
propagation and the spread of resistance genes, although a trend of change is 
clearly seen. While the strain that caused the outbreak at the VTH was 
multiresistant, the resistance was predictable, and any suspicion of MRSP 
infection could therefore be swiftly responded to. The dispersal of resistance 
genes across a plethora of STs has made such predictions impossible, as some 
isolates may be resistant to nearly all tested antimicrobials, while others are solely 
resistant to methicillin. 
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5.5.2 Geographical distribution of MRSP in Finland (unpublished) 
Specimens with S. pseudintermedius were received from all except one region of 
the Finnish mainland: Lapland. The number of specimens yielding S. 
pseudintermedius ranged from 18 to 1651 among different regions. Southern 
Finland was most represented, both in the number of clinical specimens (n = 
1651) and isolates investigated by molecular methods (n = 330). A summary of 
the different CCs and STs per region is presented in Figure 10. The proportion of 
MRSP among all S. pseudintermedius from each region is presented in Figure 11. 
 
Figure 10 Distribution of methicillin-resistant Staphylococcus pseudintermedius (MRSP) clonal 
complexes and sequence types (ST) per region in Finland and the proportion of MRSP 
among clinical S. pseudintermedius isolates (screening specimens excluded) from the 
whole study period. The data are based on the extrapolation of MLST analysis results 
to the corresponding PFGE cluster. The numbers in parentheses indicate the number 
of isolates investigated by molecular methods (including screening specimens) for 
each region. Only one isolate from Northern Finland was investigated, and it belonged 
to ST640. 
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Figure 11 Number of clinical specimens and the proportion of MRSP in separate Regional State 
Administrative Agency regions investigated at the Clinical Microbiology Laboratory of 
the Faculty of Veterinary Medicine, University of Helsinki, in 2011–2015 that yielded 
MRSP (methicillin-resistant Staphylococcus pseudintermedius) or MSSP (methicillin-
resistant S. pseudintermedius). 
While most small animals in Finland do live in the southern parts, this region is 
clearly overrepresented in this study. It is, however, surprising to see that despite 
this, the proportion of MRSP is very similar in specimens from different regions. 
Also, the composition of the MRSP population is very comparable among the two 
regions where most isolates were investigated, Southern and South-Western 
Finland. More information is, however, required before any inference may be 
made on the distribution of MRSP in Finland. Nevertheless, based on the 
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available data, it would seem reasonable to expect MRSP to be distributed fairly 
equally nationwide. 
5.6 The changing role of MRSP 
During the MRSP outbreak at the VTH (2010–2011), it seemed clear that MRSP 
was a healthcare-associated (HA) rather than a community-associated (CA) 
pathogen. However, it may be challenging to classify infections into HA-MRSP 
and CA-MRSP in veterinary medicine. One problem is the lack of commonly 
accepted definitions for HA infections. In humans, MRSA infections are classified 
as HA or CA, while the former is subdivided into community-onset and hospital-
onset (Klevens et al., 2007). Community-onset HA-MRSA is defined as a case 
with at least one of the following risk factors: the presence of an invasive device 
at time of admission; a history of MRSA infection or colonization; a history of 
surgery, hospitalization, dialysis, or residence a in long-term care facility in the 
previous year. Hospital-onset cases are defined as cases with positive culture 
results from a normally sterile site obtained >48 h after admission, and may have 
≥1 of the community-onset risk factors (Klevens et al., 2007). CA-MRSAs are 
defined as cases that do not have the previous risk factors. Hospital stays are 
usually shorter for pets than humans, especially for outpatient surgery (day 
surgery). As such, it would be expected to see far more community-onset HA-
MRSP, as infection usually takes a couple of days to develop. It is therefore 
questionable whether post-procedure infections are correctly classified as HA. 
While the number of HA-MRSP cases has declined, at least at the VTH (data 
not shown), CA-MRSP is probably on the rise. The shift in clonality is one piece 
of evidence for this; if MRSP would be predominantly HA, one would perhaps 
expect to see a small number of different clones appearing continuously in the 
population. Indeed, as previously noted, it has been suggested that CC71 isolates 
be classified as HA-MRSP outright (Kasai et al., 2016). Moreover, HA-MRSP 
would probably manifest itself as the cause of numerous HA infections, which are 
currently quite rare at the VTH. Nonetheless, a possible shift from HA to CA 
spread increases the likelihood of low-risk patients (i.e. patients without known 
risk factors) becoming at least contaminated, if not colonized, with MRSP. A near 
identical development to this was seen with MRSA in human healthcare, as it 
began as a HA problem, but soon began spreading in the community (Holzknecht 
et al., 2010; Woodford and Livermore, 2009). The shift in the method of spread 
does not mean that veterinary facilities are irrelevant to the spread of MRSP. They 
still retain a role as hubs where animals and bacteria of different origins, as well 
as selective pressure by antimicrobials, are present. The importance of infection 
control in veterinary premises should therefore be stressed as an imperative 
means of preventing the spread of resistance. 
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5.7 Antimicrobial resistance 
5.7.1 Resistance among clinical S. pseudintermedius isolates (III) 
 
Results were available from a total of 1958 clinical S. pseudintermedius isolates. 
Of these, 1471 (75%) were from specimens from private clinics, while 487 were 
from the VTH. The isolates were mainly from dogs, comprising 1928 isolates 
(98%), while 18 isolates (0.9%) originated from cats. One S. pseudintermedius 
isolate was from a guinea pig. In eleven cases (0.6%), the species had not been 
recorded. The majority of specimens (n = 1507; 77%) were obtained from 
superficial sites, such as ears and skin, while 284 (15%) were from deep lesions 
(e.g. deep wounds, abscesses, or synovial fluid). The bacterium was also 
discovered from urine (n = 98; 5%), respiratory specimens (n = 6; 0.3%), and 
blood cultures (n = 2; 0.1%). The rest (n = 61; 3%) were from cultured agar plates 
that had been sent to the laboratory for species identification and susceptibility 
testing. 
The overall proportion of oxacillin (methicillin) resistance among S. 
pseudintermedius was 14% (n = 266). While this overall percentage is lower than 
that in 2011 (17%), it is important to note that the MRSP outbreak at the VTH 
probably contributed significantly to the number that year. Non-susceptibility 
data for all tested antimicrobials for MRSP, MSSP, and overall, are presented in 
Table 14. The proportion of non-susceptible isolates per year varied only slightly 
for each antimicrobial, and no statistically significant trends were detected (Figure 
12). 
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Table 14 Antimicrobial non-susceptibility among clinical Staphylococcus pseudintermedius 
isolates from mid-2011 to the end of 2015 in Finland. 
*, Statistically significant (P < 0.001) difference between MRSP and MSSP; †, consistent data only 
available for 2015, as the extended panel was only investigated for MRSP or otherwise MDR isolates 
prior to this; MRSP, methicillin-resistant S. pseudintermedius; MSSP, methicillin-susceptible S. 
pseudintermedius; non-S, non-susceptible; n, number of isolates. 
 
 
 
Figure 12  Non-susceptibility percentages by year with 95% CI for clinical Staphylococcus 
pseudintermedius isolates in Finland from mid-2011 to the end of 2015. Cochran-
Armitage trend test P-values were: 0.14 for CLI (clindamycin); 0.14 for ERY 
(erythromycin); 0.86 for FUS (fusidic acid); 0.12 for OXA (oxacillin); 0.22 for SXT 
(sulfamethoxazole/trimethoprim); 0.40 for TET (tetracycline). 
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Clindamycin* 85.7 80.8-89.6 265 
 
22.2 20.2-24.3 1678 
 
30.8 28.8-32.9 1947 
Erythromycin* 85.7 80.8-89.6 266 
 
21.8 19.9-23.9 1678 
 
30.5 28.5-32.6 1949 
Fusidic acid 24.5 19.5-30.2 265 
 
24.3 22.3-26.4 1677 
 
24.4 22.5-26.4 1946 
Oxacillin* 100 98.2-100 266 
 
0 0.0-0.3 1682 
 
13.7 12.2-15.3 1948 
Tetracycline* 74 68.2-79.1 265 
 
33.3 31.1-35.6 1675 
 
38.8 36.6-41.0 1944 
Trimethoprim/ 
Sulfamethoxazole* 
47.7 41.6-53.9 266 
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Amikacin 0 0.0-2.1 219 
 
0 0.0-0.9 547 
 
0 0.0-1.2 393 
Chloramphenicol* 46.9 29.5-65.0 32 
 
15 10.6-20.8 207 
 
18.4 13.7-24.2 228 
Doxycycline* 28.8 18.6-41.4 66 
 
4.7 2.8-7.7 342 
 
6.1 4.0-9.1 392 
Enrofloxacin* 50.4 44.0-56.8 248 
 
2.6 1.7-4.0 793 
 
7.3 5.0-10.4 395 
Gentamicin* 44.8 38.5-51.2 248 
 
2.5 1.6-3.9 795 
 
6.6 4.4-9.6 395 
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A complete basic panel antibiogram was recorded for 1932 (99%) isolates. Of 
these, 17% (321 isolates) were MDR. The most common MDR profile (78/321; 
24%) was lincosamides/macrolides–oxacillin–trimethoprim/sulfamethoxazole–
tetracycline. Twelve isolates were non-susceptible to all six antimicrobials 
investigated, while 36% (700/1932) were fully susceptible. 
Non-susceptibility to antimicrobials was significantly higher among MRSP 
isolates than MSSP isolates for all antimicrobials, except for fusidic acid, for 
which non-susceptibility was around 24% in both. Similar findings apply to 
MRSA and MSSA (Livermore et al., 2002). Resistance to fusidic acid among S. 
pseudintermedius has varied between studies. In Sweden, 20% of isolates were 
resistant to fusidic acid in 2015 (MIC ≥ 1 mg/L) (SWEDRES-SVARM, 2016), 
which is similar to our results. In Norway, nearly half of S. pseudintermedius 
isolates investigated were fusidic acid resistant (MIC ≥1 mg/L) (Norstrom et al., 
2009). On the other hand, an Italian study did not find fusidic acid resistance in 
S. (pseud)intermedius (Vanni et al., 2009). 
A recent report from Sweden details resistance among S. pseudintermedius 
collected from skin lesions (SWEDRES-SVARM, 2016). Although our data also 
include isolates from other sources, the difference in oxacillin resistance, in 
particular, is exceptional, being 2% in the Swedish data and 14% in our data for 
2015. Similar differences can be seen among other tested antimicrobials, which is 
concerning. These differences may reflect contrasts in the use of antimicrobials 
and infection control policies in these countries. This may be reflected in the high 
proportion of animals receiving antimicrobials in the different studies. In study I, 
over 90% of MRSP-positive and over 60% of MRSP-negative patients had 
received antimicrobials. In study II, over 50% of the dogs enrolled had been 
treated with antimicrobials within the past year, and in study III, 22% of animals 
from which S. pseudintermedius was isolated from a clinical specimen were 
receiving antimicrobials during sampling. Among patients from which screening 
specimens had been obtained, this number was 29%. While it is likely that some 
bias is present, since animals from which specimens were obtained had visited 
the veterinarian at least once (except for guide dogs, from which specimens were 
taken at the Guide Dog School), these high numbers raise concerns about the use 
of antimicrobials in small animals in Finland. National reports confirm that the 
usage of antimicrobials in Sweden is lower than in Finland, and that Swedish dogs 
are prescribed antimicrobials with a more narrow spectrum (FINRES-Vet, 2015; 
SWEDRES-SVARM, 2016) 
Due to the high resistance towards commonly used antimicrobials in S. 
pseudintermedius in Finland, clinicians are strongly encouraged to take 
specimens for bacterial cultures early in the disease process to ensure the efficacy 
of the intended treatment. Moreover, the use of local, or non-antimicrobial 
therapy should be emphasized as a viable alternative to many infections. These 
issues are also discussed in the newly published national guidelines on the use of 
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antimicrobials in animals (Finnish Food Safety Authority and the Faculty of 
Veterinary Medicine, 2016). In addition, since S. pseudintermedius is a common 
finding in infections associated with dermatological diseases, it is vital that any 
underlying disease process is properly controlled to avoid the unnecessary use of 
antimicrobials. More research is required to determine the value of antimicrobial 
therapy in patients when underlying conditions have been controlled. 
Furthermore, the high resistance among S. pseudintermedius could warrant 
making MRSP a notifiable animal disease in Finland, as it is in Sweden 
(SWEDRES-SVARM, 2016). 
5.7.2 Oxacillin susceptibility histograms and production of beta-
lactamases (unpublished) 
 
The distribution of oxacillin ZOI diameters for 2011 and 2015 is presented in 
Figure 13. 
 
Figure 13 Zone diameter distributions for oxacillin in 2011 and 2015 for Staphylococcus 
pseudintermedius at the Clinical Microbiology Laboratory of the Faculty of Veterinary 
Medicine in 2011–2015. The vertical dashed line designates the breakpoint for 
susceptible isolates. 
 
In 2007, Jones et al. (2007) published data on the susceptibility of S. 
(pseud)intermedius. The data indicated that the number of oxacillin-resistant 
isolates clearly increased in 2001–2005. The study also divided the oxacillin data 
into highly resistant (ZOI for oxacillin ≤ 10 mm), resistant (ZOI 11–17 mm), and 
susceptible (ZOI ≥ 18 mm). The proportion of highly resistant isolates remained 
fairly constant, 20–30%. The same cannot be said for our data (Figure 13). In 2011, 
roughly 80% of MRSP isolates were highly resistant to oxacillin. Four years later, 
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the same number was roughly 36%, a clear shift in the distribution of zone 
diameters. Note, however, that many isolates in 2011 belonged to the VTH 
outbreak clone. It is likely, although not studied here, that the shift in the 
distribution reflects the shift in clonality, as a larger number of different clones 
would spread out the histogram among methicillin-resistant isolates. The shift in 
oxacillin susceptibility may also make it more difficult to identify carriers of 
MRSP with the screening method used in our studies, as an increased ZOI for 
oxacillin indicates a decrease in oxacillin MICs of the MRSP population. 
There were 421 MSSP isolates in the 2016 laboratory data. Beta-lactamase 
production was tested in 252 cases (60%). Out of these, 231 (92%; CI95% 88–94%) 
were beta-lactamase positive. The proportion of beta-lactamase producers among 
MSSP isolates was somewhat higher in our data than that of a Norwegian study, 
where only 70% of S. pseudintermedius isolates produced beta-lactamase, i.e. 
were resistant to penicillin (Norstrom et al., 2009). Similar resistance rates to 
penicillin (72%) have been seen in Australia (Bean and Wigmore, 2016). However, 
a Lithuanian study determined, by PCR detection of the blaZ gene, that 94% of S. 
pseudintermedius isolates from diseased dogs were resistant to penicillin 
(Ruzauskas et al., 2016). This number is very similar to our result. Interestingly, 
in a multinational European study, penicillin resistance in S. pseudintermedius 
was reported to be only ~20% (Ludwig et al., 2016). This was, however, 
determined by a MIC method using breakpoints based on human data. 
Due to the high proportion of MSSP isolates being resistant to beta-lactamase 
susceptible antimicrobials (e.g. penicillin, ampicillin, and amoxicillin), the use of 
these drugs in the treatment of skin infections cannot be recommended. On the 
other hand, the use of beta-lactamase-resistant drugs, such as amoxicillin-
clavulanic acid or cephalexin, may increase the risk of the patient becoming an 
MRSP carrier. 
5.8 Limitations of the study 
As with any study, there are limitations to consider. In study I, the quality of the 
data was dependent on how well information had been recorded in the patient 
management software. This type of bias is, however, expected to be equally 
distributed among cases and controls. Additionally, information related to patient 
care, such as the number of times the animal was handled or the exact placing of 
the patient (e.g. cage number), was unavailable. Such data could help in 
understanding the dynamics of the outbreak. It may be considered a limitation 
that not all patients could be screened for MRSP upon admission. As a result, it 
cannot be ruled out that some of the patients may have had MRSP prior to 
admission. During an outbreak, however, it is not realistic, nor necessary, to 
screen every patient in order to determine their admission status. As discussed 
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above, the likelihood of a community acquired MRSP ST71 was very low when all 
evidence was considered. 
In study III, the information on risk factors, such as antimicrobial therapy, 
was prone to reporting bias, as this information is more likely to be reported if the 
animal is receiving treatment. This is, however, unlikely to have impacted on our 
results, as the minimum data coverage for risk factors was 88% in that study. 
Also, due to the imperfect sensitivity of the MRSP screening method used in 
the studies, some degree of misclassification is likely to have occurred. Test 
specificity was probably high, as all isolates were characterized after isolation. 
Currently, no reference standard for the screening of MRSP is available. Other 
studies have, however, used similar methods to the one utilized here (Gomez-
Sanz et al., 2011; Paul et al., 2011). Studies regarding MRSA in humans or 
livestock, where similar methods have been utilized, have reported sensitivities of 
up to 98% (Pletinckx et al., 2012; Veenemans et al., 2013; Verkade et al., 2011a; 
Verkade et al., 2011b). However, as indicated in section 2.7, commercial MRSA-
selective agars may contain cefoxitin as the selective antimicrobial. The outbreak 
strain was highly resistant to oxacillin (MIC >256 mg/L), and was therefore also 
likely to have been highly resistant to cefoxitin (Bemis et al., 2009; Bemis et al., 
2006; Bemis et al., 2012). Based on our internal evaluation of the method used, 
the limit of detection is approximately 10 colony forming units, provided that 
MRSP has an oxacillin MIC ≥4 mg/L. Also, the extension of the incubation time 
to 48 hours for initially negative plates increases the sensitivity (personal 
observation), and has revealed isolates with MICs as low as 2 mg/L. It is therefore 
unlikely that a significant amount of misclassification would have occurred. 
The sensitivity of the method is also dependent on the sampling. The sample 
sites were selected based on two criteria: 1) sites reported in the literature to give 
a high yield of MRSP and 2) convenience. Sampling sites vary between studies, 
but the nose, mouth, and perineum appear in many (see section 2.7 for a detailed 
review). A study by Windahl et al. (2012) reported that the pharynx, closely 
followed by the perineum, yielded the most MRSP isolations of the positive 
sample occasions. The collection of swabs from the pharynx is, however, difficult 
(and even dangerous) and can cause discomfort to the dog. Thus, this sample site 
was omitted. 
Regarding the molecular epidemiology, it is worth noting that specimens 
mainly originated from Southern Finland and may thus not reflect the resistance 
situation in the entire country. On the other hand, the proportion of private clinic 
specimens rose from 16% in 2011 to 47% in 2015, with nearly 200 submitting 
clinics, which increased the geographical coverage. Furthermore, PFGE was used 
as a screening method to find candidates for MSLT and SCCmec typing without 
having to type all MRSP isolates, which was not feasible. It is therefore possible 
that there are other, as yet unidentified, STs among the isolates. However, apart 
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from one instance where multiple isolates had been typed from a PFGE cluster, 
all belonged to the same CC. 
In the susceptibility data of study III, there may be more than one isolate from 
the same animal, which may have caused bias in the data. Such bias is, however, 
likely to be minimal due to the large number of isolates, and because such isolates 
would probably be distributed evenly among susceptible and resistant 
populations and over the years. For molecular data, only the first MRSP isolate of 
an animal was stored.
Conclusions 
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6 Conclusions 
The use of strict hygiene protocols and barrier nursing are necessary in combating 
an MRSP outbreak. 
 
MRSP has a low prevalence (3%) among guide dogs in Finland, and a similar 
proportion (2.5%) of clinical specimens from small animals revealed MRSP. 
Among screening specimens taken from patients with risk factors for MRSP, over 
9% carry the bacterium. 
 
The low number of clinical MRSP isolates from feline specimens, and the lack of 
MRSP-positive cats in screening specimens, indicates that the targeted screening 
of feline patients is unnecessary and unlikely to be cost effective. 
 
Antimicrobial therapy, a prolonged hospital stay, and frequent veterinary visits 
are identifiable risk factors for MRSP. 
 
Antimicrobial resistance for several antimicrobials among Finnish S. 
pseudintermedius isolates is high and a cause for concern, especially as 14% of 
isolates are methicillin resistant. This emphasizes the need to obtain a 
bacteriological specimen whenever antimicrobial therapy is indicated. Moreover, 
the use of non-antimicrobial therapy for infections should be considered 
whenever feasible. 
 
The epidemiology of MRSP has shifted away from a primarily clonal spread to 
being spread both clonally and through the transfer of resistance genes. 
 
A worryingly high proportion of patients in the studies were receiving or had 
received antimicrobials. Decisive action is required to reduce the consumption of 
antimicrobials in small animals.  
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7 Future aspects 
There are still many important aspects to investigate regarding MRSP in Finland.  
The most important need is undoubtedly to investigate the actual prevalence of 
MRSP in dogs, as well as in specific risk populations, such as dermatological 
patients. This should preferably be done with a new, more sensitive method than 
the one used in this study, perhaps utilizing PCR for rapid screening of specimens 
that need to be cultured. Such a project is already underway. 
In addition, more information is needed on how long animals carry MRSP and 
to establish guidelines on how many consecutive negative screening specimens 
are required to declare an animal free of MRSP.  Data on this have already been 
collected by our research team. It would also be beneficial to determine whether 
decolonization therapy for MRSP is indicated for small animal patients prior to 
surgical intervention, or whether such therapy is effective at all. 
Furthermore, to maintain a grasp of the MRSP situation in Finland in the 
future, it would be preferable if molecular analyses were carried out yearly for 
representative MRSP isolates. Moreover, making MRSP a notifiable animal 
disease would help in mapping the extent of Finland’s MRSP situation. In 
addition, more frequent, preferably annual, reports on the resistance patterns and 
proportions for common animal pathogens could help clinicians adapt their 
therapeutic regime to immediately select an appropriate antimicrobial. This 
would hopefully also bring forth the problem of resistance. One possibility would 
be to annually publish resistance data in a concise form in the Finnish Veterinary 
Journal. 
It could also be beneficial to explore the usefulness of novel methods, such as 
MALDI-TOF, as tools for rapidly identifying and typing MRSP isolates. In 
addition, investigating the clinical efficacy of antimicrobial treatment for different 
infections would be important in order to reduce the consumption of 
antimicrobials.
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Appendix 1 
AscI PFGE dendogram of the MRSP isolates investigated (Study II). 
All isolates were also investigated using SmaI restriction (see text). 
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Appendix 2 
Gel image of the products of isolate P-781 and positive controls after SCCmec PCR. (Study II) 
ctr, control; SCCmec I ctr, Staphylococcus aureus NCTC 10442; SCCmec II ctr, Staphylococcus aureus 
ATCC® BAA-1720™; SCCmec III ctr, Staphylococcus aureus ATCC® BAA-43™, SCCmec V ctr, 
Staphylococcus aureus JCSC 6944; SCCmec VI ctr, Staphylococcus aureus ATCC® BAA-42™. 
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SmaI PFGE dendrogram with antimicrobial resistance profiles of methicillin-resistant Staphylococcus 
pseudintermedius isolated at the Laboratory of Clinical Microbiology of the Faculty of Veterinary Medicine, 
University of Helsinki, in 2010–2014 (Study III). PC, private (veterinary) clinic; VTH, Veterinary Teaching 
Hospital (of the University of Helsinki); O, oxacillin; E, erythromycin; C, clindamycin; S, 
trimetoprim/sulfametoxazol; T, tetracycline; F, fusidic acid; R, enrofloxacin; G, gentamicin; A, amikacin; NT, 
non-typeable; -, missing value; ST, sequence type; SCCmec, Staphylococcal Cassette Chromosome mec. 
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Appendix 4 
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AscI PFGE dendrogram with antimicrobial resistance profiles of methicillin-resistant Staphylococcus 
pseudintermedius isolated at the Laboratory of Clinical Microbiology of the Faculty of Veterinary Medicine, 
University of Helsinki, in 2010–2014 (Study III). PC, private (veterinary) clinic; VTH, Veterinary Teaching 
Hospital (of the University of Helsinki); O, oxacillin; E, erythromycin; C, clindamycin; S, 
trimetoprim/sulfametoxazol; T, tetracycline; F, fusidic acid; R, enrofloxacin; G, gentamicin; A, amikacin; NT, 
non-typeable; -, missing value; ST, sequence type; SCCmec, Staphylococcal Cassette Chromosome mec. 
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Appendix 5 
Combinations of result from SCCmec M-PCR 1 and 2 that gave a non-typeable outcome (Study III). A–G 
denote PCR products. A, mecA (286 bp); B, ccrC (518 bp); C, ccrA2-ccrB (937 bp); D, ccrA4-ccrB4 (1287 
bp); E, mecA-mecI (1963 bp); F, mecA-IS431 (804 bp); G, mecA-IS1272 (2827 bp); n, number of isolates 
that gave each SCCmec result. 
 
